KALEV NÕUPUU

Autosomal-recessive Stargardt disease: phenotypic heterogeneity and genotype-phenotype associations
KALEV NÕUPUU

Autosomal-recessive Stargardt disease: phenotypic heterogeneity and genotype-phenotype associations
Department of Ophthalmology, University of Tartu, Estonia

This dissertation has been accepted for the commencement of the degree of Doctor of Philosophy (Medicine) on the 15th of March, 2017 by the Council of the Faculty of Medicine, University of Tartu, Estonia

Supervisors: Kuldar Kaljurand, MD, PhD, Department of Ophthalmology, Faculty of Medicine, University of Tartu, Estonia
Professor Rando Allikmets, PhD, Department of Ophthalmology and Department of Pathology & Cell Biology, Columbia University, USA

Reviewers: Professor Pille Taba, MD, PhD, Department of Neurology and Neurosurgery, University of Tartu, Estonia
Professor Katrin Õunap, MD, PhD, Department of Clinical Genetics, University of Tartu, Estonia

Opponent: Associate Professor Bart Peter Leroy, MD, PhD, Department of Ophthalmology and Center of Medical Genetics, Ghent University Hospital & Ghent University, Belgium.
Chairman and Head of Department, Department of Ophthalmology, Ghent University Hospital & Ghent University, Belgium.
Attending Physician, Ophthalmic Genetics and Visual Electrophysiology, Division of Ophthalmology and Center for Cellular and Molecular Therapeutics, The Children's Hospital of Philadelphia, USA.

Commencement: June 14th, 2017
This study was supported by grants from the National Eye Institute/National Institutes of Health (Bethesda, MD, USA) EY021163, EY019861, and EY019007 (Core Support for Vision Research), Foundation Fighting Blindness (Owings Mills, MD, USA), and an unrestricted funds from Research to Prevent Blindness (New York, NY, USA) to the Department of Ophthalmology, Columbia University.

ISSN 1024–395X

Copyright: Kalev Nõupuu, 2017

University of Tartu Press
www.tyk.ee
## TABLE OF CONTENTS

LIST OF ORIGINAL PUBLICATIONS ............................................................... 7

ABBREVIATIONS ....................................................................................... 8

1. INTRODUCTION .......................................................................................... 9

2. LITERATURE REVIEW ................................................................................ 10
   2.1. Topographic anatomy of the retina .......................................................... 10
   2.2. Histological layers and different cell types in the retina ......................... 11
      2.2.1. Histological layers of the retina ..................................................... 11
      2.2.2. Main cell types in the retina ......................................................... 12
   2.3. Physiology of the retina ........................................................................... 16
      2.3.1. Phototransduction cascade .............................................................. 16
      2.3.2. Visual cycle and chromophore restoration ......................................... 16
   2.4. Stargardt retinal dystrophy ..................................................................... 17
      2.4.1. ABCA4 function in visual cycle and pathogenesis of STGD1 ............. 19
      2.4.2. Structural and functional assessment of the retina in STGD1 ................ 20
      2.4.3. Phenotypic heterogeneity in STGD1 ................................................. 24
      2.4.4. Genotype-phenotype associations in STGD1 ..................................... 26
      2.4.5. Differential diagnosis of STGD1 ...................................................... 27

3. AIMS OF THE STUDY ................................................................................ 29

4. MATERIALS AND METHODS ................................................................. 30
   4.1. Study subjects and clinical evaluation .................................................... 30
   4.2. Retinal imaging ...................................................................................... 31
   4.3. Electrophysiology .................................................................................. 32
   4.4. Genetic analyses ..................................................................................... 32
   4.5. Statistics ................................................................................................ 33
   4.6. Ethics ..................................................................................................... 33

5. RESULTS .................................................................................................... 34
   5.1. Phenotypic expression and outer retinal abnormalities in young patients with STGD1 (Paper I) .................................................. 34
      5.1.1. Clinical and genetic evaluation of the young STGD1 patients ................ 34
      5.1.2. Phenotypic evaluation of the young STGD1 patients .......................... 34
      5.1.3. Longitudinal changes in the cohort .................................................. 36
      5.1.4. Quantitative analysis of outer retinal layers in young STGD1 patients .......................................................... 36
   5.2. Optical gap phenotype in STGD1 (Paper II) .......................................... 38
      5.2.1. Clinical and phenotypic evaluation of STGD1 patients with the optical gap phenotype ................................................. 39
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.2.2.</td>
<td>Structural staging of the optical gap phenotype with SD-OCT</td>
<td>39</td>
</tr>
<tr>
<td>5.2.3.</td>
<td>Longitudinal analysis of the optical gap phenotype in STGD1</td>
<td>42</td>
</tr>
<tr>
<td>5.2.4.</td>
<td>Phenotype-genotype association in STGD1 with the optical gap phenotype</td>
<td>43</td>
</tr>
<tr>
<td>5.3.</td>
<td>A subtype of foveal sparing phenotype in STGD1 resembling HCQ retinopathy (Paper III)</td>
<td>44</td>
</tr>
<tr>
<td>5.3.1.</td>
<td>Clinical and genetic evaluation of the patients</td>
<td>44</td>
</tr>
<tr>
<td>5.3.2.</td>
<td>Structural analysis of the retina</td>
<td>45</td>
</tr>
<tr>
<td>5.3.3.</td>
<td>Lesion formation</td>
<td>46</td>
</tr>
<tr>
<td>6.</td>
<td>DISCUSSION</td>
<td>50</td>
</tr>
<tr>
<td>6.1.</td>
<td>Early stage retinal structural changes in STGD1</td>
<td>50</td>
</tr>
<tr>
<td>6.2.</td>
<td>Sub-phenotypes in STGD1 detectable on SD-OCT</td>
<td>52</td>
</tr>
<tr>
<td>6.3.</td>
<td>Genotype-phenotype associations in STGD1</td>
<td>56</td>
</tr>
<tr>
<td>7.</td>
<td>CONCLUSIONS</td>
<td>58</td>
</tr>
<tr>
<td>8.</td>
<td>REFERENCES</td>
<td>60</td>
</tr>
<tr>
<td>9.</td>
<td>SUMMARY IN ESTONIAN</td>
<td>72</td>
</tr>
<tr>
<td>10.</td>
<td>ACKNOWLEDGEMENTS</td>
<td>76</td>
</tr>
<tr>
<td>11.</td>
<td>PUBLICATIONS</td>
<td>77</td>
</tr>
<tr>
<td></td>
<td>CURRICULUM VITAE</td>
<td>115</td>
</tr>
<tr>
<td></td>
<td>ELULOOKIRJELDUS</td>
<td>117</td>
</tr>
</tbody>
</table>
LIST OF ORIGINAL PUBLICATIONS

Paper I:

Paper II

Paper III

* These authors contributed equally to this work.

Contribution of the author to the preparation of the original publications:

Paper I: Working with clinical and genetic databases, participation in the design of the study, patient recruitment, retinal imaging, data analysis and interpretation as well as participation in the manuscript writing process.

Paper II: Participation in the patient recruitment and retinal imaging, working with clinical and genetic databases, proposing the research idea, planning the study design, analyzing the phenotypic and clinical data, proposing the phenotype grading system and detecting the genotype-phenotype association, preparing the figures and writing the first manuscript draft.

Paper III: Participation in the patient recruitment and retinal imaging, working with clinical and genetic databases, presenting the research idea, designing the study, analyzing the data (images and clinical data), preparing the figures and writing the first manuscript draft.

The articles are reprinted with the permission of the copyright owners.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCA4</td>
<td>Retinal-specific ATP-binding cassette transporter</td>
</tr>
<tr>
<td>ABCA4</td>
<td>A gene which encodes the ABCA4 transporter</td>
</tr>
<tr>
<td>AF</td>
<td>Autofluorescence</td>
</tr>
<tr>
<td>AMD</td>
<td>Age-related macular degeneration</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>A2E</td>
<td>N-retinylidene-N-retinylethanolamine</td>
</tr>
<tr>
<td>BCVA</td>
<td>Best-corrected visual acuity</td>
</tr>
<tr>
<td>BEM</td>
<td>Bull’s eye maculopathy</td>
</tr>
<tr>
<td>cSLO</td>
<td>Confocal scanning laser ophthalmoscope</td>
</tr>
<tr>
<td>ECD</td>
<td>Exocyttoplamic domain</td>
</tr>
<tr>
<td>ELM</td>
<td>External limiting membrane</td>
</tr>
<tr>
<td>EZ</td>
<td>Ellipsoid zone</td>
</tr>
<tr>
<td>(ff)ERG</td>
<td>(Full-filed) electroretinography</td>
</tr>
<tr>
<td>FAF</td>
<td>Fundus autofluorescence</td>
</tr>
<tr>
<td>GCL</td>
<td>Ganglion cell layer</td>
</tr>
<tr>
<td>HCQ</td>
<td>Hydroxychloroquine (Plaquenil)</td>
</tr>
<tr>
<td>ICC</td>
<td>Intraclass correlation coefficient</td>
</tr>
<tr>
<td>ILM</td>
<td>Internal limiting membrane</td>
</tr>
<tr>
<td>INL</td>
<td>Inner nuclear layer</td>
</tr>
<tr>
<td>IPL</td>
<td>Inner plexiform layer</td>
</tr>
<tr>
<td>IS</td>
<td>Inner segment</td>
</tr>
<tr>
<td>IZ</td>
<td>Interdigitation zone</td>
</tr>
<tr>
<td>mfERG</td>
<td>Multifocal electroretinography</td>
</tr>
<tr>
<td>NBD</td>
<td>Nucleotide binding domain</td>
</tr>
<tr>
<td>NGS</td>
<td>Next-generation sequencing</td>
</tr>
<tr>
<td>ONL</td>
<td>Outer nuclear layer</td>
</tr>
<tr>
<td>OPL</td>
<td>Outer plexiform layer</td>
</tr>
<tr>
<td>OS</td>
<td>Outer segment</td>
</tr>
<tr>
<td>PERG</td>
<td>Pattern electoretinography</td>
</tr>
<tr>
<td>RPE</td>
<td>Retinal pigment epithelium</td>
</tr>
<tr>
<td>RDH8</td>
<td>Retinol dehydrogenase 8</td>
</tr>
<tr>
<td>(SD)-OCT</td>
<td>(Spectral-domain) optical coherence tomography</td>
</tr>
<tr>
<td>STGD1</td>
<td>Stargardt disease</td>
</tr>
<tr>
<td>TMD</td>
<td>Transmembrane domain</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

Stargardt disease (STGD1) is the most common form of juvenile-onset macular dystrophy with the estimated prevalence between 1:8000 to 1:10 000 worldwide (Michaelides et al., 2003). Although it is not a very common disease, it causes progressive visual loss from childhood or early adolescence affecting substantially a person’s everyday life.

The disease is caused by mutations in the *ABCA4* gene, which encodes the photoreceptor specific transporter vital in the visual cycle (Allikmets et al., 1997b). The dysfunctional transporter leads to photoreceptor degeneration and visual deterioration (Molday and Zhang, 2010). To date, more than 1000 disease causing mutations have been described resulting in remarkable allelic and phenotypic heterogeneity (Zernant et al., 2014b).

The modern imaging methods enable to detect and assess phenotypic expression on the histological level providing further insights into the pathophysiology of the disease. Furthermore, multimodal imaging enables to expand the phenotypic spectrum permitting to detect new genotype-phenotype associations. New insights into the pathophysiology, phenotypes and genotype-phenotype correlations are essential in the light of ongoing research on gene and stem cell therapy in STGD1. Therefore, the present study was designed to research the phenotypes and possible phenotype-genotype associations in STGD1 using multimodal imaging. We assessed and analyzed early stage retinal structural changes in young patients with STGD1 and provided further insight into the pathophysiology of the disease. In addition, we acquired some new diagnostic information that may facilitate early diagnosis of STGD1.
2. LITERATURE REVIEW

2.1. Topographic anatomy of the retina

Retina is a light-sensitive neural tissue in the inner surface of the eye responsible for converting light into electrical signals, a process called phototransduction (Sung and Chuang, 2010). It is part of the central nervous system, as it is embryonically derived from the forebrain (Purves et al., 2004). Direct connection with the brain is ensured by the retinal ganglion cell axons which form the optic nerve and transmit the visual impulses to the brain. The optic nerve head, also called optic disc, could be visualized with the ophthalmoscope. It does not contain any photoreceptors and is an entry site for the major retinal blood vessels (Figure 1).

![Figure 1. Topography of the fundus. The optic nerve head, also called optic disc, is formed by axons of the ganglion cells. It is an entrance site for major retinal blood vessels. Macula situates between the retinal temporal arcades and is centered by fovea. The center of the macula is cone-dominated and the peripheral retina is rod-dominated.](image)

Topographically, retina can be divided into the central and peripheral retina. The central retina is called macula and it is located between the retinal temporal arteries covering a diameter of approximately 5.5 mm. The macula has central depression with the diameter of 1.5 mm called fovea (Yanoff and Duker, 2004). Ophthalmoscopically, fovea is recognized by the foveal reflex. The loss of foveal reflex could be an early sign of various retinal diseases, including STGD1 (Reynolds and Olitsky, 2011). The bottom of the fovea is called foveola with the diameter of 350 µm. It has the highest concentration of cone photoreceptors.
providing the highest visual acuity and resolution as well as color vision (Yanoff and Duker, 2004, Reynolds and Olitsky, 2011). The peripheral retina is rod-dominated and runs from the temporal retinal arteries to the *ora serrata* (Ross and Pawlina, 2011). The main function of the peripheral retina is peripheral and night vision (Yanoff and Duker, 2004).

### 2.2. Histological layers and different cell types in the retina

#### 2.2.1. Histological layers of the retina

The retina has a laminate structure with anatomically distinct layers and different cell types (Ross and Pawlina, 2011). There are 10 distinct histological layers in the retina: the pigment epithelium layer (RPE), the photoreceptor layer, the external limiting membrane (ELM), the outer nuclear layer (ONL), the outer plexiform layer (OPL), the inner nuclear layer (INL), the inner plexiform layer (IPL), the ganglion cell layer, the nerve fiber layer and the inner limiting membrane (ILM) (Ross and Pawlina, 2011) (Figure 2).

*Figure 2.* Retina is a light-sensitive tissue lining the inner surface of the eye (A: blue). It contains a variety of cells responsible for visual phototransduction, processing and transmission (B: cones (C) and rods (R), bipolar cells (B), horizontal cells (H), amacrine cells (A), Müller cells (M) and ganglion cells (G)). These cells and their axons form distinct histological layers within the retina (C): pigment epithelium layer (RPE), photoreceptor layer (OS, IS), external limiting membrane (not marked), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform layer (IPL), ganglion cell layer (GCL), nerve fiber layer (not marked) and inner limiting membrane (not marked) (Sung and Chuang, 2010) (with permission from the Rockefeller University Press).
The outermost layer is the RPE layer, which separates the neural retina from the choroid (Ross and Pawlina, 2011). It is a monolayer of RPE cells on the 1–4 μm elastic membrane called Bruch’s membrane (Reynolds and Olitsky, 2011). Due to the close affinity to each other, a term RPE-Bruch’s membrane complex is sometimes used (Karampelas et al., 2013).

The layer next to the RPE cells is the photoreceptor layer, which consists of photoreceptor light sensitive outer segments (OS), responsible of phototransduction, and inner segments (IS) (Ross and Pawlina, 2011). The nuclei of the photoreceptors form the outer nuclear layer, which is separated from the photoreceptor layer by the external limiting membrane (Ross and Pawlina, 2011). The ELM is formed by the apical ends of Müller cells forming junctional complexes between each other and photoreceptors (Bringmann et al., 2006, Reichenbach and Bringmann, 2013), preventing the passage of large molecules into the inner parts of the retina (Ross and Pawlina, 2011). Each photoreceptor cell body has an axon with synaptic terminal connections with interneuron cells. These connections form the outer plexiform layer responsible for visual impulse transmission. Interneuron cells which have direct connections with photoreceptors are bipolar- and horizontal cells, while additional interneurons responsible for visual processing are amacrine and interplexiform cells (Reynolds and Olitsky, 2011, Ross and Pawlina, 2011). Nuclei of the interneurons and Müller cells are in the inner nuclear layer and more connections between interneurons (amacrine, bipolar, interplexiform) and ganglion cells are formed in the inner plexiform layer. Visual impulses are processed and transferred to ganglion cells, which are situated in the ganglion cell layer. The axons of the ganglion cells form the nerve fiber layer and the optic nerve, which transmit the visual impulse to the brain (Purves et al., 2004, Ross and Pawlina, 2011). The innermost layer is called the internal limiting membrane and it consists of flattened processes of Müller cells (Ross and Pawlina, 2011).

### 2.2.2. Main cell types in the retina

#### Retinal pigment epithelium (RPE)

Retinal pigment epithelial cells are melanin containing cells that form the outer blood retinal barrier and separate choriocapillaris from the photoreceptors (Reynolds and Olitsky, 2011). These cells form tight junctions between each other preventing free flow of molecules between neural retina and choroid. Instead, they facilitate active transport which is essential for the photoreceptor and RPE metabolism (Marmor and Wolfensberger, 1998, Strauss, 2005). The retinal pigment epithelial cell layer is vital for photoreceptor functioning and survival and, in addition to outer blood-retinal barrier function, it serves as a pump, keeping the subretinal space dehydrated and neural retina attached to the RPE. Furthermore, it supports the retinal development by secreting growth factors and cytokines (Strauss, 2005). Different antioxidants in the RPE cells protect cells from oxidative damage (Boulton and Dayhaw-Barker, 2001). The retinal
pigment epithelium is vital in the visual cycle and retinoid metabolism. It participates in the regeneration of chromophores and provides the visual cycle with additional retinol by absorbing it from the choroidal circulation (Marmor and Wolfensberger, 1998, Strauss, 2005, Simo et al., 2010).

Photoreceptors are non-dividing cells in an environment of potentially harmful free radicals, therefore regular renewal and turnover is essential for photoreceptor proper functioning (Sung and Chuang, 2010, Molday and Zhang, 2010). This reparation mechanism is ensured by the RPE cells, which constantly phagocytose photoreceptor outer segment tips, while new ones are formed and replaced by the photoreceptors. In fact, 10% of outer segment tips are replaced daily (Tsybovsky et al., 2010). In the process of regular turnover of photoreceptor outer segments, there is a progressive accumulation of lipofuscin pigment to the RPE cells. This pigment is an end-product of outer photoreceptor segment degradation that accumulates gradually with age (Kennedy et al., 1995). Chemically, it is a heterogeneous mixture of lipids, proteins and different fluorescent compounds (Kennedy et al., 1995). Lipofuscin is a fluorescent pigment enabling to visualize the RPE cells with autofluorescence (AF) imaging (Delori et al., 1995). Excessive lipofuscin is toxic to the RPE cells and it has a fundamental role in the pathophysiology of STGD1 (Cideciyan et al., 2004, Sparrow et al., 2000, Sparrow and Boulton, 2005). Another pigment in the RPE is melanin, which serves as a free radical stabilizer and a light absorber lowering the glare (Simo et al., 2010).

**Photoreceptor cells**

There are two types of photoreceptor cells in the retina: cones and rods. Cones are less numerous than rods, accounting for 3–5% of photoreceptors, but they are the major photoreceptor type in the fovea and the only one present in the foveola (Sung and Chuang, 2010, Mustafi et al., 2009). Cones are responsible of color and high resolution vision in bright light. Rods, on the other hand, dominate the rest of the retina and are responsible for vision in low light intensity (Sung and Chuang, 2010).

The photoreceptor cell consists of the outer segment, the connecting cilia, the inner segment, the nucleus and the axon with synaptic terminal (Sung and Chuang, 2010, Ross and Pawlina, 2011) (Figure 3). Outer segments in both, cones and rods, are cylindrically modified cilia which contain flattened, lamellar-shaped membrane discs, arrayed perpendicular to the axis of the outer segments (Sung and Chuang, 2010). The lipid membrane of these discs contains various molecules essential in visual function, including visual pigments and the ABCA4 transporter (Ross and Pawlina, 2011, Mustafi et al., 2009). The outer segment is connected with the inner segment via the connecting cilia. The inner segment has two parts: an outer ellipsoid and inner myeloid part. The myeloid region is mainly responsible for protein synthesis, containing Golgi apparatus, endoplasmic reticulum and free ribosomes, whereas the ellipsoid region contains numerous mitochondria that provide photoreceptors with the adenosine
triphosphate (ATP) energy (Ross and Pawlina, 2011, Reynolds and Olitsky, 2011). A photoreceptor signal is transmitted to the outer plexiform layer via the axon and synaptic terminal (Reynolds and Olitsky, 2011).

**Figure 3.** Structure of the rod photoreceptor. Photoreceptors consist of the outer-and inner segment, connected with the connecting cilium, the nucleus and synaptic terminal (A). The outer segment contains the outer segment discs and inner segment contains various organelles vital for photoreceptor functioning (A). The RPE cells participate in the outer segment renewal by phagocytosing the tips of the outer segments (A). Outer segment contains lamellar discs surrounded by cytoplasm and plasma membrane (B). The disc membrane contains various molecules important in phototransduction and the visual cycle, including photopigment (not shown) and ABCA4 transporter (C) (Molday and Zhang, 2010) (with permission from Elsevier).

**Interneuron cells**

The cell bodies of the interneurons are located in the inner nuclear layer. There are four types of interneurons responsible for visual signal transmission and image processing: bipolar, horizontal, amacrine and interplexiform cells (Ross and Pawlina, 2011, Reynolds and Olitsky, 2011). These cells form complex neuroretinal circuitries in the OPL and IPL through synapses with photoreceptors and ganglion cells (Ross and Pawlina, 2011).
Ganglion cells

Ganglion cells are located in the GCL forming contacts with the bipolar and amacrine cells (Reynolds and Olitsky, 2011). The axons of the ganglion cells form NFL and the optic nerve. The main function of these cells is to conduct visual impulses to the brain via the optic nerve. However, there is a small sub-group of photoreceptive ganglion cells that express photopigment melanopsin. These intrinsic photosensitive retinal ganglion cells are non-image-forming, but they influence circadian rhythms, pupillary light reflex and sleep (Hattar et al., 2002, Schmidt et al., 2011, O'Brien et al., 2002).

Glial cells in the retina

There are three types of glial cells in the retina: Müller cells, astrocytes and microglia (Fischer et al., 2010). Müller cells are the major type of glial cells in the retina spanning their processes throughout the entire retina filling the most of the extracellular space (Bringmann et al., 2006, Reichenbach and Bringmann, 2013). The nuclei of Müller cells are located in the INL and their basal and apical ends form the inner and outer limiting membranes, respectively (Ross and Pawlina, 2011). Müller cells provide structural support as well as metabolic support to the other retinal cells (Bringmann et al., 2006, Reichenbach and Bringmann, 2013). They are able to phagocytose fragments of retinal cells and protect photoreceptors from damage by releasing neurotrophic factors and antioxidants (Reichenbach and Bringmann, 2013, Bringmann et al., 2006). Furthermore, Müller cells participate in the formation and conduction of visual impulse by participating in the cone visual cycle and regulating synaptic activity in the retina (Reichenbach and Bringmann, 2013, Wang and Kefalov, 2011). Müller cells have been shown to act like optical fibers, guiding light through the inner retinal layers minimizing the light scattering and improving the quality of vision (Franze et al., 2007).

Astrocytes enter the developing retina via the optic nerve and are mostly located in the nerve fiber layer where they envelope the axons of the ganglion cells and retinal blood vessels (Chan-Ling, 1994). Astrocytes participate in the formation of retinal vessels, the blood-retina barrier and they provide neurotropic as well as mechanical support for degenerating axons (Vecino et al., 2016).

Microglial cells are tissue-resident phagocytosing cells situating mostly in the inner retinal layers. In normal conditions microglia is important in maintaining retinal homeostasis. They phagocytose cell debris and secrete growth factors (Vecino et al., 2016). However, it has been shown that in various pathological conditions, including retinal degenerative diseases like age-related macular degeneration (AMD) and retinitis pigmentosa, extensive microglia activation leads to inflammation, which adds its detrimental effect on photoreceptors health (Vecino et al., 2016, Ma et al., 2009, Ma et al., 2012, Langmann, 2007). In fact, it has been shown in a retinitis pigmentosa rat model, that suppressing microglial activation may delay photoreceptor death (Noailles et al., 2014).
2.3. Physiology of the retina

2.3.1. Phototransduction cascade

The process where energy of light is converted into electrical neural signal is called phototransduction (Roosing et al., 2014). The process takes place in the photoreceptor outer segments via the activation of the visual pigment (Sung and Chuang, 2010). The visual pigment is a compound molecule of light sensitive chromophore and opsin molecule located in the lipid membrane of outer segment discs (Wang and Kefalov, 2011, Palczewski, 2012). The photo-sensitive chromophore is vitamin A aldehyde 11-cis retinal and the molecule is the same in both rods and cones. However, there are 4 types of opsin molecules depending on the absorption peak (Reynolds and Olitsky, 2011). The visual pigment in rods is called rhodopsin and in cones, there are 3 types of cone visual pigments with different absorption maxima (Mustafi et al., 2009). The mixture of different cones with different visual pigments and absorption peaks result in the ability to detect colors (Mustafi et al., 2009). The rods, on the other hand, have only one type of visual pigment which is responsible for achromatic vision in dim light (Mustafi et al., 2009).

The visual cascade starts with the capture of a photon and isomerization of 11-cis retinal to all-trans retinal. This reaction changes the conformation of the opsin molecule and activates the photopigment. In the cytosolic side of the disc membrane opsin is combined with a G-protein called transducin, which activates the enzyme cGMP phosphodiesterase (PDE). This activation reduces the cGMP concentration in the cytoplasm resulting in closure of cGMP-gated cation channels located in the photoreceptor outer segment plasma membrane. The closure of these channels leads to photoreceptor hyperpolarization resulting in reduced neurotransmitter glutamate secretion in the synaptic terminal (Palczewski, 2012, Yau, 1994, Yau and Hardie, 2009).

The restoration of the visual pigment is thereafter crucial. The chromophore is restored in the visual cycle and the visual pigment is rebuilt. Deactivation of the phototransduction cascade and restoring the photoreceptor sensibility is ensured by a cascade of enzymatic reactions (Lamb and Pugh, 2006).

2.3.2. Visual cycle and chromophore restoration

Phototransduction cascade is dependent on the visual cycle, responsible for recycling the all-trans-retinal to 11-cis-retinal vital for restoring the visual pigment (Palczewski, 2012). This continuous process takes place in the photoreceptor outer segments and the RPE cells. In cone system, additional Müller cell-based visual cycle has been reported (Reichenbach and Bringmann, 2013, Wang and Kefalov, 2011).

Absorption of photon by visual chromophore isomerizes 11-cis retinal to all-trans retinal, which is released to the disc lumen. Free all-trans retinal diffuses to the cytoplasmatic leaflet of the disk membrane, where NADPH-dependent
retinol dehydrogenase (RDH8) reduces all-trans retinal to all-trans retinol (Palczewski, 2012). A fraction of all-trans retinal and 11-cis retinal form compounds with the disk membrane phospholipids which cannot diffuse freely across the disk membrane (Quazi et al., 2012, Quazi and Molday, 2014). These compounds are flipped out from the disk lumen by ABCA4 transporter after which they can be reduced to retinol (Quazi et al., 2012, Quazi and Molday, 2014). All-trans retinol is transferred out of the photoreceptors to the extracellular compartment, where it binds to the inter-photoreceptor retinoid binding protein (IRBP) and is transported to the RPE cells (Wang and Kefalov, 2011, Saari, 2012). In the RPE it binds to cellular retinol-binding protein type 1 (CRBP1) and is esterified by lecithin retinol acyltransferase (LRAT) to all-trans retinyl ester (Saari, 2012). This ester is further hydrolyzed and isomerized by RPE65 to 11-cis retinol. 11-cis retinol is bound to cellular retinaldehyde-binding protein (CRALBP) and oxidized to 11-cis retinal by 11-cis retinol dehydrogenase after which 11-cis retinal is transported back to the photoreceptors with IRBP to regenerate the visual pigment (Saari, 2012). Additional retinol is constantly added from the choroid blood circulation by the RPE cells (Chen and Heller, 1977).

2.4. Stargardt retinal dystrophy

Stargardt disease is the most common form of inherited macular dystrophy with the estimated prevalence of 1:8000 to 1:10 000 (Michaelides et al., 2003). The disease is caused by mutations in the ABCA4 gene, which is on chromosome 1 and encodes the ABCA4 transporter (Allikmets et al., 1997b). The transporter is vital in the visual cycle and the dysfunctional protein leads to lipofuscin over-accumulation in the RPE cells resulting in RPE and photoreceptor degeneration (Sparrow and Boulton, 2005, Cideciyan et al., 2004). The symptoms usually start in the first or second decade with progressive visual deterioration (Michaelides et al., 2003). Lipofuscin accumulation is responsible for STGD1-associated features such as increased fundus autofluorescence (FAF) (Cideciyan et al., 2004, Boon et al., 2008), yellow pisciform flecks, and progressive atrophy of the outer retinal layers. Early clinical signs of STGD1 are atrophic changes in the macula and yellowish flecks, but there is remarkable phenotypic heterogeneity within the clinical spectrum of STGD1 (Fishman et al., 1999, Fishman, 1976, Fujinami et al., 2013d, Cella et al., 2009, Lois et al., 2001, Westeneng-van Haaften et al., 2012). Distinguishing STGD1 from other phenotypically similar diseases is often difficult with just a clinical exam, therefore ABCA4 genetic screening and application of several imaging methods, such as SD-OCT and FAF imaging, are important (Figure 4).
Figure 4. Different imaging methods of the retina in the healthy eye: color photo (A), an autofluorescence image (B) and an optical coherence tomography image (C). The SD-OCT enables to visualize different retinal layers (inset): outer retinal layers are retinal pigment epithelium (RPE), the interdigitation zone (IZ), the ellipsoid zone (EZ), the external limiting membrane (ELM) and the outer nuclear layer (ONL) (from Edward S. Harkness Eye Institute).

Stargardt disease is autosomal recessive dystrophy requiring mutations on both chromosomes to cause the disease (Allikmets et al., 1997b), however, complete sequencing of \(ABCA4\) coding and intron-exon boundaries reveal two \(ABCA4\) mutations in only 65–70% of patients and one \(ABCA4\) mutation in 15–20% of patients (Zernant et al., 2011). Detection of only one \(ABCA4\) mutation with “typical” STGD1 phenotype could be explained from both genetic and clinical aspects. The second mutation could be large deletion, insertion or deep intronic variant, which all elude the routinely used screening methods, such as direct PCR-based sequencing, or the phenotype could be a phenocopy caused by mutation(s) in other genes (Zernant et al., 2011, Zernant et al., 2014b). Furthermore, the second mutation could be present in modifier genes or in promoter/enhancer regions near the \(ABCA4\) gene which influence the \(ABCA4\) expression (Zernant et al., 2011, Westeneng-van Haaften et al., 2012).
2.4.1. ABCA4 function in visual cycle and pathogenesis of STGD1

ABCA4 is a photoreceptor specific transporter vital for the visual cycle. It is a member of the ATP-binding cassette transporter superfamily and has two nucleotide binding domains (NBD) for ATP binding and hydrolyzing, two transmembrane domains (TMD) and two exocytoplasmic domains (ECD) for substrate binding and transportation (Molday and Zhang, 2010). The protein is encoded by the \textit{ABCA4} gene on chromosome 1 and is located in the outer segment disc rims of rods and cones (Sun and Nathans, 1997, Molday et al., 2000) (Figure 3).

In the process of photo-transduction, all-trans retinal is released. The molecule contains an aldehyde group, which makes it highly reactive and potentially harmful to the photoreceptors. Therefore all-trans retinal needs to be detoxified and reduced to all-trans retinol (Quazi and Molday, 2014, Quazi et al., 2012). The enzyme essential for this reaction is retinol dehydrogenase 8 (RDH8) in the cytoplasm of the photoreceptor outer segments (Rattner et al., 2000). Therefore, all-trans retinal has to get out from the disc lumen to be accessible to the RDH8. Most of the all-trans retinal diffuses freely across the lipid bilayer but a fraction form compounds with the membrane phospholipid called phosphatidylethanolamine. The formed compound is called N-retinylidene-phosphatidylethanolamine and it cannot diffuse across disc membrane by itself, but employs the ABCA4 transporter for that purpose (Quazi et al., 2012). The ABCA4 transporter flips N-retinylidene-phosphatidylethanolamine from the lumen to the cytoplasmatic leaflet of the disc membranes where it diffuses back to phosphatidylethanolamine and all-trans-retinal (Quazi et al., 2012). Thereafter the all-trans retinal can be reduced to all-trans retinol by RDH8. In addition, ABCA4 transports free phosphatidylethanolamine in the same direction (Quazi et al., 2012). Recently it has been showed that similar process is true for 11-cis retinal, where excess 11-cis retinal may form compounds with phosphatidylethanolamine and ABCA4 transports N-11-retinylidene-phosphatidylethanolamine out from the disc lumen (Quazi and Molday, 2014). Therefore, ABCA4 transporter helps to clear the photoreceptors from the excessive 11-cis and all-trans retinal, both highly reactive and potentially toxic molecules to the photoreceptors (Quazi et al., 2012, Quazi and Molday, 2014).

Mutations in the \textit{ABCA4} gene lead to dysfunctional ABCA4 transporter resulting in N-retinylidene-phosphatidylethanolamine accumulation and formation of bisretinoid complexes in the lumen side of disc membrane (Molday and Zhang, 2010). There is constant renewal of the photoreceptor outer segments by the RPE cell phagocytosis. During the process these diretinoid complexes deposit to the lysosomes of the RPE cells where major lipofuscin fluorophore, A2E (N-retinylidene-N-retinylethanolamine) is formed and deposited (Sparrow et al., 2008, Tsybovsky et al., 2010, Ben-Shabat et al., 2002). A2E containing lipofuscin has harmful effects on the RPE cell functioning via various effects. These include lysosomal dysfunction (Holz et al., 1999), membrane disruption (Sparrow et al., 1999), loss of antioxidant effectiveness...
(Shamsi and Boulton, 2001), photo-toxicity (Schutt et al., 2000, Sparrow et al., 2000), immune dysregulation (Zhou et al., 2009, Zhou et al., 2006) and DNA damage (Sparrow et al., 2003). As the RPE cells are vital in photoreceptor function, progressive RPE cell degeneration leads to photoreceptor death.

The excessive lipofuscin accumulation is believed to be the hallmark of the pathogenesis in STGD1 (Sparrow and Boulton, 2005, Cideciyan et al., 2004, Burke et al., 2014), however, there is increasing evidence that neuro-inflammation in the retina plays also an important role in the pathogenesis of retinal degenerations (Zhou et al., 2009, Kohno et al., 2013, Xu et al., 2009, Radu et al., 2011, Ma et al., 2012, Langmann, 2007, Zhou et al., 2006). Photo-exposure to A2E and all-trans retinal dimers leads to formation of photo-oxidation products which are capable of activating complement and induce low-grade inflammation (Zhou et al., 2009, Zhou et al., 2006, Sparrow et al., 2000, Schutt et al., 2000). Furthermore, the migration of microglia and macrophages into subretinal space has been described in Abca–/– mice (Radu et al., 2011, Kohno et al., 2013) and it has been demonstrated that the deposition of A2E to the RPE cells and microglia increases microglial activation and alters the complement regulation in vitro as well as in vivo (Ma et al., 2013, Kohno et al., 2013, Zhou et al., 2009, Zhou et al., 2006). Microglia accumulates the bisretinoids and lipofuscin primary by phagocytosing surrounding degenerating photoreceptors and RPE cells (Ma et al., 2013, Lei et al., 2012, Kohno et al., 2013, Xu et al., 2009). In addition, the RPE cells themselves modulate microglia by producing chemokines after phagocytosing the photoreceptor outer segments (Kohno et al., 2013). Therefore, the activation of immune cascade affects the environment and different cell types in the outer retina contributing to the pathogenesis of STGD1.

Furthermore, it has been shown that excess all-trans retinal and possibly 11-cis retinal can cause photoreceptor damage directly (Maeda et al., 2009, Maeda et al., 2014, Maeda et al., 2012, Chen et al., 2012). However, there is still debate whether the primary cells affected in STGD1 are RPE cells or photoreceptors (Sparrow and Boulton, 2005, Cideciyan et al., 2004, Duncker et al., 2014, Gomes et al., 2009, Burke et al., 2011).

### 2.4.2. Structural and functional assessment of the retina in STGD1

#### Spectral-domain optical coherence tomography and retinal structural changes in STGD1

Optical coherence tomography (OCT) is a non-invasive imaging method enabling to create cross sectional retinal images in vivo (Sakata et al., 2009) It uses light waves to measure their reflection time delay and intensity from different retinal structures by comparing it with the reference reflection path (Drexler and Fujimoto, 2008). This enables to visualize different retinal layers correlating with retinal histology and detect even minor disease-associated structural changes (Spaide and Curcio, 2011, Staurenghi et al., 2014). The image quality and resolution of OCT has improved substantially within the last
decade providing researches new perspectives in terms of clinical research and understanding of the retinal diseases.

The spectral-domain optical coherence tomography (SD-OCT) retinal images exhibit different intensity bands correlating with the anatomical layers of the retina (Spaide and Curcio, 2011, Staurenghi et al., 2014). Four distinct hyper-reflective fine bands are visualized in the outer retina associated with Müller cells, photoreceptors and RPE cells (Spaide and Curcio, 2011) (Figure 4, C). The outermost hyper-reflective band represents RPE/Bruch’s membrane complex formed mainly by the RPE cells. Anteriorly, a fine elusive band is attached to the RPE layer. The band is called the interdigitation zone and is possibly formed by the RPE apical processes enveloping cone outer segment tips. The third band is called the ellipsoid zone, thought to represent the ellipsoid zone of the photoreceptor inner segment just above the cilia. The hyper-reflectivity is thought to be caused by intensely packed mitochondria in this region (Spaide and Curcio, 2011, Staurenghi et al., 2014). Disappearance of this band represents photoreceptors integrity loss correlating well with visual acuity decline (Wong et al., 2012, Testa et al., 2012). The innermost hyper-reflective band represents the external limiting membrane formed by junctional complexes of Müller cell apical ends to each other and with photoreceptors (Spaide and Curcio, 2011, Staurenghi et al., 2014).

Stargardt disease is retinal dystrophy affecting mostly the outer retina layers: the RPE and the photoreceptor associated layers (Burke et al., 2011, Duncker et al., 2014, Park et al., 2015, Ergun et al., 2005) (Figure 5). It has been shown that greater photoreceptor loss on OCT imaging corresponds to lower visual acuity (Ergun et al., 2005), furthermore, the ellipsoid zone integrity correlates also well with other studies which assess photoreceptor health including multifocal electroretinography (mERG), full-field electroretinography (fERG) and microperimetry (Testa et al., 2012). However, changes in retinal thickness have also been detected in the inner retinal layers. Extrafoveal inner nuclear layer thickening associated with the regions of outer nuclear layer thinning have been noted, probably due to the retinal remodeling following the photoreceptor loss (Huang et al., 2014). Furthermore, changes in peripapillary nerve fiber layer thickness in STGD1 have been demonstrated (Genead et al., 2011, Pasadhika et al., 2009). These findings confirm that retina is a complex tissue with vigorous communication between different cell types and changes in the outer retina lead to inner retina remodeling and laminopathy (Huang et al., 2014).

Choroidal thickness measurements in STGD1 have revealed that the mean subfoveal total choroidal thickness as well as subfoveal large choroidal vessel thickness is significantly reduced in STGD1 (Adhi et al., 2015).
Figure 5. “Classical” phenotype in STGD1. The color photo of the fundus exhibits bull’s-eye like atrophic lesion in the macula and yellowish flecks throughout the entire fundus (A, arrows). Macular atrophy corresponds to hypo-autofluorescent central lesion on the fundus autofluorescence image due to the atrophy of the RPE layer. Hyper-AF dots are seen throughout the fundus (white arrow), representing flecks. Hypo-autofluorescent dots are seen on the nasal side representing resorbed flecks (B). Disruption and atrophy of the outer retinal layers are seen in the macula on SD-OCT image (C) (from Edward S. Harkness Eye Institute).

Fundus autofluorescence imaging in STGD1

The major source for short-wavelength FAF signal is lipofuscin which is accumulated in the RPE cells (Delori et al., 1995, Sparrow and Boulton, 2005). Lipofuscin contains a mixture of fluorophores, which could be excited with a light source. After the excitation it emits back signal with longer wave length, which can be detected and recorded. The signal is generated by illuminating the fundus with an argon laser source within blue spectrum (488 nm) and the resultant FAF signal is recorded with confocal scanning laser ophthalmoscope (cSLO) with bandpass filter having short wavelength cutoff 495 nm (Keane and Sadda, 2014, Schmitz-Valckenberg et al., 2008).

The lipofuscin concentration in the RPE cells increase with age, but in STGD1 it is pathologically extensive (Delori et al., 2001, Burke et al., 2014), therefore FAF imaging enables to detect early stage pathological changes in
STGD1, including an increased FAF signal and characteristic fleck patterns (Cideciyan et al., 2004, Lois et al., 2004, Fujinami et al., 2013b, Burke et al., 2014). As FAF imaging provides information about the health and integrity of the RPE cells, absence of or the reduced FAF signal indicates mostly to RPE atrophy or death (Holz et al., 2001, Boon et al., 2008).

Cideciyan et al proposed a model of ABCA4 disease sequence where initially there is an accumulation of lipofuscin leading to a progressive increase in the FAF signal and hyper-AF fleck formation in the posterior pole followed by FAF signal reduction and loss in later stages due to the RPE dysfunction and death accompanied by slowing of the retinoid cycle and increasing photoreceptor degeneration (Cideciyan et al., 2004).

As STGD1 cases have very variable phenotype, different FAF patterns have been described, whereas the most typical is central hypo-autofluorescent (hypo-AF) lesion reflecting chorioretinal macular atrophy surrounded by small hyper-autofluorescent (hyper-AF) pisciform flecks (Boon et al., 2008) (Figure 5). Measurements of FAF signal intensity in STGD1 with quantitative AF demonstrate that different genotypes provide different fluorescence levels and certain genotype-phenotype associations are possible (Duncker et al., 2014).

**Functional assessment of the retina with electroretinography in STGD1**

Retinal function is assessable with many different methods, while one of the most objective methods is electroretinography (ERG). Full-field ERG enables to assess the general function of the photoreceptors as well as the function of other retinal cells in the inner nuclear layer (Holder et al., 2010). Depending on the stimuli and background illumination it is possible to record the function of cone and rod photoreceptors separately. The full-field ERG generates mass response of the cones, rods or both, therefore in isolated macular disease the full-field ERG is usually normal (Holder et al., 2010). Consequently, multifocal ERG (mERG) or pattern ERG (PERG) is essential in assessing the macular function (Holder et al., 2010).

Multifocal ERG examines the spatial aspect of the cone system function in the central retina mapping the electrical activity of cones in the central visual field (Holder et al., 2010, Kretschmann et al., 1998). Pattern ERG, on the other hand, does not use light stimulus, but black and white checkerboard instead, assessing the central retinal photoreceptor function as well as ganglion cell function (Holder et al., 2010).

Stargardt disease is macular dystrophy suggesting that there should be abnormalities in the PERG and mERG, but normal full-field ERG. However, STGD1 shows a wide range of full-field ERG abnormalities (Fishman, 1976, Lois et al., 2001, Zahid et al., 2013, Fujinami et al., 2013a), based on which the disease could be divided into 3 separate groups: Group 1 exhibits PERG abnormalities, but normal full-field photopic and scotopic responses, Group 2, in addition to PERG abnormality, exhibits changes in photopic ERG and Group 3 exhibits decreased responses in both photopic and scotopic ERG responses (Lois et al., 2001).
Furthermore, the differences in groups are not explained on the basis of differences in age of onset and duration of the disease, suggesting that these could be separate phenotypic subgroups rather than different stages of the disease progression (Lois et al., 2001). Indeed, it would be reasonable to assume that the phenotype might predict cone-rod function on full-field ERG, meaning that lesions confined to the macula have normal ERG, while more wide-spread disease has more affected ERG, (Fishman, 1976, Zahid et al., 2013, Cella et al., 2009) but it is not always the case. The retinal phenotype with macular lesion could have very prominent changes in full-field ERG and more prominent fundus changes could have normal full-field ERG (Oh et al., 2004, Lois et al., 2001).

Full-field ERG may have prognostic value in terms of STGD1 progression since it has been shown that abnormalities in maximum stimulation A-and B-wave amplitudes have significantly higher average rate of scotoma progression compared with the patients with normal full-field ERG (Zahid et al., 2013). Fujinami et al showed that patients with STGD1 who present initially with normal full-field ERG (Group1) have most favorable prognosis, as only 22% of patients have ERG deterioration, while in patients in ERG groups 2 or 3 have ERG deterioration in 65% and 100% of patients, respectively. Association between best-corrected visual acuity (BCVA) and ERG as well as between ERG and age of onset was also detected, meaning that lower BCVA was associated with more affected ERG and the earlier the onset, the more affected was the ERG (Fujinami et al., 2013a).

Multifocal ERG is a sensible tool for detecting early functional abnormalities of the macula in STGD1 even before apparent morphological macular change or visual acuity loss, furthermore, the area of dysfunction is usually larger than predicted by morphological studies (Kretschmann et al., 1998).

2.4.3. Phenotypic heterogeneity in STGD1

The clinical expression of the disease was first described by a German ophthalmologist Karl Stargardt in 1909, but the association with the ABCA4 gene was discovered almost 90 years later (Allikmets et al., 1997b, Stargardt, 1909). Since then, more than 1000 disease causing mutations in the ABCA4 gene have been found resulting in remarkable phenotypic and genotypic heterogeneity in ABCA4-associated retinopathies (Zernant et al., 2014b). In addition to phenotypic heterogeneity in STGD1 in terms of clinical expression, fundus and electroretinography findings as well as in age of onset, mutations in ABCA4 have also been reported in cone-rod dystrophy (Cremers et al., 1998, Maugeri et al., 2000), autosomal recessive retinitis pigmentosa (Cremers et al., 1998, Martinez-Mir et al., 1998) and AMD (Allikmets et al., 1997a). However, it has to be noted that autosomal-recessive cone-rod dystrophy is also considered as a phenotypic version of STGD1 (Lois et al., 2001). Sometimes the term fundus flavimaculatus is used in a subgroup of patients, with widespread fundus flecks without apparent macular atrophy, but currently it is considered as a phenotypic
variant of the STGD1 rather than a separate entity (Fishman, 1976, France-
schetti and Francois, 1965, Michaelides et al., 2003). Overall, STGD1 typically
begins with early macular atrophic changes and yellowish flecks at the posterior
pole, but there is remarkable phenotypic heterogeneity with variable age of
onset and clinical expression (Michaelides et al., 2003). Most of STGD1 patients
have the disease onset in the first two decades of life (Michaelides et al., 2003)
with the central visual loss, reduced dark adaption (Fishman et al., 1991) and
disturbances in the color vision (Mantyjarvi and Tuppyainen, 1992, Vanden-
broucke et al., 2015), but it could vary largely (Westeneng-van Haaften et al.,
2012).

Based on disease onset, STGD1 has been divided into early-onset and late-
onset disease (Westeneng-van Haaften et al., 2012, Yatsenko et al., 2001,
Lambertus et al., 2015) or childhood-onset and adult-onset STGD1 (Fujinami et
al., 2015). Phenotypes in early-onset STGD1 are more severe compared with the
late-onset STGD1 (Fujinami et al., 2015, Lambertus et al., 2015). It has been
shown that childhood-onset STGD1 is associated with more severe and faster
visual acuity deterioration and more common generalized cone and rod system
dysfunction compared with adult-onset STGD1 (Fujinami et al., 2015). Late-
onset STGD1 patients have usually milder phenotype with adult or even elderly
age of onset, better visual acuity and slower progression (Westeneng-van Haaften
et al., 2012). Many late-onset patients exhibit foveal sparing phenotype (Weste-
neng-van Haaften et al., 2012).

Foveal sparing is a sub-phenotype where foveal region remains relatively
intact maintaining partial or full function despite relatively advanced disease
(Fujinami et al., 2013d, van Huet et al., 2014). The foveal sparing phenotype is
not specific to STGD1, but it has been described in other retinal degenerations
as well (Duncker et al., 2015, Querques et al., 2016, Forte et al., 2013). In
STGD1, there has been a report of tendency to higher frequency of p.R2030Q
and lower incidence of p.G1961E variant (Fujinami et al., 2013d), however
another study did not confirm the association (van Huet et al., 2014).

A less common phenotype in STGD1 is optical gap, also known as foveal
cavitation or optically empty lesion (Cella et al., 2009, Leng et al., 2012, Ritter
et al., 2013). The phenotype is detectable on SD-OCT as focal subfoveal loss of
ellipsoid zone reflectivity, representing subfoveal photoreceptor loss leaving an
optically empty space (Leng et al., 2012). The phenotype is not specific to
STGD1; it has also been described in solar retinopathy (Jain et al., 2009), laser
induced retinal injury (Zhang et al., 2016), rod monochromatism (Greenberg et
al., 2014) and RPIL1 maculopathy (Park et al., 2010).

Based on phenotypic expression, multiple grading systems for the disease
have been suggested. Fishman et al divided STGD1 patients into 4 phenotypic
stages: Stage 1 disease represents central macular atrophy with para- or peri-
foveal flecks; Stage 2 represents flecks throughout the entire posterior pole
often extending anterior to the vascular arcades and/or nasal to the optic disc,
Stage 3 presents with mostly resorbed flecks and Stage 4 represents widespread
RPE and chorioretinal atrophy throughout the fundus (Fishman, 1976).
Electrophysiological abnormalities were noted from Stage 3 indicating that phenotype affects the ERG. Lois et al, on the other hand, did not find that ERG abnormalities correlated with age of onset or disease duration, suggesting that there could be distinct ERG phenotypes depending on abnormalities in cone and rod function (Lois et al., 2001).

Flecks in STGD1 are not universal, but may develop later in the disease course (Fujinami et al., 2015, Lambertus et al., 2015). In some patients with childhood-onset STGD1, fine macular dots have been described (Fujinami et al., 2015).

2.4.4. Genotype-phenotype associations in STGD1

Genotype-phenotype associations are difficult to determine due to extensive allelic heterogeneity. Furthermore, determining the severity of specific allele is impeded because compound heterozygous patients harbor two different alleles and the number of patients sharing the same allelic combinations is generally low. The phenotypic expression of the same genotype may vary between different cases or even within the same pedigree, indicating a possibility of modifying genes and environmental factors (Lois et al., 1999, Schindler et al., 2010, Michaelides et al., 2007). Previous studies have hypothesized that phenotype severity, including age of onset, is determined by mutations effect on ABCA4 activity, meaning that the lower the ABCA4 residual activity the more severe is the phenotype (Sun et al., 2000, Shroyer et al., 1999, van Driel et al., 1998).

Missense mutations mapping outside the functional ABCA4 region, probably retaining partial ABCA4 activity, have shown to be associated with milder disease and later-onset STGD1 (Yatsenko et al., 2001), while mutations abolishing ABCA4 function, exhibit severe phenotype with early-onset panretinal disease (Cremers et al., 1998, Wiszniewski et al., 2005, Fujinami et al., 2013a, Fujinami et al., 2015). Fujinami et al demonstrated further that childhood-onset STGD1 have higher portion of deleterious ABCA4 variants compared with adult-onset STGD1 and 71% patients with two deleterious ABCA4 variants in childhood-onset STGD1 were in the ERG Group 3 (Fujinami et al., 2015).

Mutations in the ABCA4 gene may phenotypically express as STGD1, cone-rod dystrophy (Cremers et al., 1998, Maugeri et al., 2000) or retinitis pigmentosa-like disease (Cremers et al., 1998, Martinez-Mir et al., 1998). It has been shown that the most severe mutations abolishing the ABCA4 function result in retinitis pigmentosa-like dystrophy, while milder mutations result in cone-rod dystrophy or STGD1 (Heathfield et al., 2013). It has to be noted that autosomal recessive cone-rod dystrophy caused by ABCA4 dysfunction has also been classified as a phenotypic variant of STGD1 belonging to ERG Group 3 (Lois et al., 2001, Fishman, 1976, Fujinami et al., 2013a). Moreover the “classical” STGD1 may progress to retina-wide disease, affecting both rod and cone induced full-field ERG responses, diagnostic to cone-rod dystrophy (Fujinami et
al., 2013a). However, some studies have shown that the ABCA4 function hypothesis does not always apply, and probably some additional factors contribute to the phenotypic expression (Cideciyan et al., 2009, Burke et al., 2012b).

Probably the most studied variant in STGD1 is the p.G1961E allele. This is not unexpected, as the p.G1961E mutation is the most frequent disease-causing ABCA4 allele seen in approximately 10% of STGD1 patients of European origin (Burke et al., 2012a). The p.G1961E allele has been associated with bull’s eye maculopathy and milder phenotypes in STGD1 (Cella et al., 2009, Fishman et al., 1999, Fujinami et al., 2013c). Cella et al studied a cohort of patients with at least one p.G1961E allele and none of the patients exhibited generalized cone or rod function loss (Cella et al., 2009). All patients presented with bull’s eye maculopathy without flecks. They concluded that the p.G196E allele in either homozygosity or compound heterozygosity confers a milder phenotype with bull’s eye lesion, later disease onset and absence of generalized retinal dysfunction (Cella et al., 2009). However, a larger study with patients homozygous for p.G1961E demonstrated that it is not always the case and exceptions are possible (Burke et al., 2012a). Furthermore, it is believed that p.G1961E has a “dominant” effect over the other allele in trans, because even if the second mutation is “severe”, the phenotype tends to be “milder” (Burke and Allikmets, 2013, Burke et al., 2014). Additionally, patients carrying the p.G1961E allele have lower FAF signal level and absence of the dark choroid phenomenon indicating lower lipofuscin accumulation with this allele (Burke et al., 2014, Fishman et al., 1999).

### 2.4.5. Differential diagnosis of STGD1

It is often difficult to distinguish STGD1 by an ophthalmic examination from other phenotypically similar retinopathies, especially if these exhibit similar hyper-AF flecks. One example is multifocal pattern dystrophy which frequently simulates STGD1 (Duncker et al., 2015, Boon et al., 2007). It is an autosomal dominant dystrophy caused by mutations in the PRPH2 gene (Boon et al., 2007). Two other autosomal dominant Stargardt-like macular dystrophies (STGD3 and STGD4), caused by mutations in ELOVL4 and PROM1 genes, respectively, have been described (Palejwala et al., 2016, Zhang et al., 2001, Kniazeva et al., 1999).

Stargardt disease could exhibit bull’s eye macular lesion even without characteristic flecks (Cella et al., 2009, Fujinami et al., 2015), therefore all conditions exhibiting bull’s eye maculopathy should be considered as a differential diagnosis. These include cone (rod) dystrophy, central areolar choroidal dystrophy, age-related macular degeneration, chronic macular hole, chloroquine/hydroxychloroquine (HCQ) retinopathy, olivopontocerebellar atrophy and ceroid lipofuscinosis (Regillo et al., 2007). Cone (rod) dystrophy is a diagnosis made via ERG and can be caused by many genes, including ABCA4 (Cremers et al., 1998, Mauger et al., 2000), which is/are mostly considered as phenotypic variant(s) of STGD1 (Lois et al., 2001). Central areolar choroidal dystrophy has
autosomal dominant inheritance, adult onset and is caused by mutation in \textit{PRPH2} (Hoyng et al., 1996). Late-onset STGD1 is sometimes confused with AMD (Westeneng-van Haaften et al., 2012, Burke et al., 2012a), while bull’s eye maculopathy in younger individuals with neurologic deficit could suggest olivopontocerebellar atrophy or lipofuscinosis (Wright et al., 2006).

Hydroxychloroquine is an anti-malaria drug commonly used in the treatment of various systemic autoimmune disorders which may cause retinopathy with bull’s eye lesion exhibiting “flying-saucer” sign on SD-OCT (Chen et al., 2010). The term “flying-saucer” sign is a variant of foveal sparing, referring to abrupt disruption of the EZ band in the parafoveal region and thinning of the outer nuclear layer, forming a so-called “flying saucer” configuration (Chen et al., 2010, Marmor, 2012, Ascaso et al., 2013, Tailor et al., 2012).
3. AIMS OF THE STUDY

1) To assess and analyze early stage retinal structural changes in young patients with STGD1 (Paper I).
2) To find, describe and analyze uncommon SD-OCT phenotypes in STGD1 and to assess retinal function in these patients (Papers II, III).
3) To detect possible genotype-phenotype associations in STGD1 (Paper II).
4. MATERIALS AND METHODS

4.1. Study subjects and clinical evaluation

All studies were conducted at the Department of Ophthalmology of the Columbia University, using clinical and genetic database involving patients with clinical diagnosis and genetic confirmation of STGD1 found to have one or two disease causing mutations in the \textit{ABCA4} gene. Within this cohort, SD-OCT and FAF (AF; 488 nm) images were available for 179 patients in Paper I and Paper II. New patients with STGD1 were constantly added to the database and followed and re-imaged once a year, therefore, for Paper III, 200 patients with the set of imaging data were available.

Each patient underwent a complete ophthalmic examination by a retinal specialist, including slit-lamp examination and dilated fundus examination. The function of the retina was assessed with full-field and multifocal ERG, while the structure was examined using color fundus photography, FAF imaging and SD-OCT. The best corrected visual acuity (BCVA) was detected in all patients, except for only one patient in Paper I, where data about BCVA were not available.

The estimated disease duration was defined to be the period from the reported age of symptomatic onset to the age at first examination.

**Phenotypic expression and outer retinal abnormalities in young patients with STGD1 (Paper I)**

Due to our clinical observation that the abnormalities in the ELM develop in younger patients who in general have shorter disease duration and earlier disease stage, we included all patients with STGD1 from the group of 179 patients who presented to the Retina Division for SD-OCT and FAF imaging before the age of 20. Therefore, these patients were imaged relatively soon after the disease onset (mean disease duration was 3.2 years). A total of 26 STGD1 patients (mean age, 12.9 years; range, 5–19 years) satisfied the inclusion criteria. The thickness and reflectivity of the ELM and EZ were measured and the data were compared with the data obtained from the SD-OCT-s from 30 age-matched controls (age range, 4–20 years; mean age, 12.5 years). Full-field ERG recordings were available and analyzed in 19 patients.

**Structural and Genetic Assessment of the ABCA4-Associated Optical Gap Phenotype (Paper II)**

Spectral-domain OCT images of 179 STGD1 patients were analyzed and 15 patients with the optical gap phenotype were identified and included to the study. Phenotypic staging was carried out and defined by two independent graders for each patient. Clinical characteristics and \textit{ABCA4} mutation profile were described and analyzed for all patients.
**Recessive Stargardt disease phenocopying hydroxychloroquine retinopathy (Paper III)**

Spectral-domain OCT images of 200 patients with STGD1 were retrospectively assessed and 8 patients with a variant of foveal sparing SD-OCT phenotype usually associated with hydroxychloroquine (HCQ) retinopathy were detected. Clinical characteristics and genetic profile of the STGD1 patients with the SD-OCT phenotype were described and analyzed.

### 4.2. Retinal imaging

Spectral-domain OCT scans, FAF and near-infrared reflectance images were acquired using the Spectralis HRA+OCT device (Heidelberg Engineering, Heidelberg, Germany). Fundus autofluorescence images were acquired by illuminating the fundus with an argon laser source (488 nm) and viewing the resultant fluorescence through a band-pass filter with a short wavelength cutoff at 495 nm. Color fundus photos were obtained with an FF 450plus Fundus Camera (Carl Zeiss Meditec AG, Jena, Germany). Foveal fixation in Paper II was assessed using fundus camera with fixation needle.

**Quantitative image analysis**

In Paper I, quantitative analyses of the ELM and EZ were conducted on high-resolution SD-OCT scans of the right eye of 24 STGD1 patients (mean age, 12.9 years; range, 5–19 years) and 30 age-matched controls (mean age, 12.5 years; range, 4–20 years).

The sampling area for each measurement was assigned to a position half the distance between the foveal center and the nasal edge of the optic disc, a location measured with the ruler tool within the ophthalmic software (Heidelberg Explorer Software; Heidelberg Engineering) (Figure 6, A). Analysis of the designated area in the macula was not possible for two patients (P10, P23) due to progressed outer retina atrophy. Thickness and reflectivity values were averages between measurements made manually by two independent observers with the ophthalmic software (Heidelberg Engineering) (Figure 6, B and C).

Reflectivity of the ELM and EZ on SD-OCT was assessed by obtaining the maximum pixel gray values (peaks) corresponding to the ELM and EZ of a vertically positioned pixel intensity profile (reflectivity profile) perpendicular to the RPE layer. Pixel intensity profiles were generated and analyzed with ImageJ software (http://imagej.nih.gov/ij/; available in the public domain of the National Institutes of Health, Bethesda, MD, USA) (Figure 6, C). Longitudinal changes were analyzed and described where possible.
4.3. Electrophysiology

Full-field scotopic and photopic electroretinograms were obtained according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standards (Marmor et al., 2009) using the Espion visual electrophysiology system (Diagnosys LLC, Littleton, MA, USA) and silver-impregnated fiber electrodes (DTL; Diagnosys LLC, Littleton, MA, USA).

Multifocal ERG in Paper 2 was recorded and analyzed with the VERIS system (VERIS EDI, San Mateo, CA, USA) using Burian-Allen contact electrode. Test was performed according to the standards and guidelines of the International Society for Clinical Electrophysiology of Vision (Hood et al., 2012).

Based on the full-field ERG findings, patients were divided into 3 groups: Group 1 exhibited pattern electroretinography abnormalities, but normal full field photopic and scotopic responses, Group 2 exhibited changes in isolated photopic function and Group 3 exhibited significant dysfunction in both the scotopic and photopic systems (Lois et al., 2001).

4.4. Genetic analyses

In Paper I, $ABCA4$ screening was first performed with the $ABCA4$ microarray for all patients. If none or one $ABCA4$ mutations were identified, then further screening was performed with next-generation sequencing (NGS).

In Papers II and III all patients were screened for $ABCA4$ variants by complete sequencing of all coding and intron/exon boundaries of the gene by either Sanger sequencing or by NGS. The next-generation sequencing was performed either with Fluidigm Custom Amplicon protocol (Access Array; Fluidigm,
South San Francisco, CA; http://www.fluidigm.com/products/access-array.html) followed by sequencing on 454 GS-FLX Fluidigm sequencer as described before (Zernant et al., 2011) or with the Illumina TruSeq Custom Amplicon protocol (Illumina, San Diego, CA), followed by sequencing on Illumina MiSeq platform (Illumina MiSeq; Illumina, Inc). The next-generation sequencing reads were analyzed and compared to the reference genome GRCh37/hg19, using the variant discovery software NextGENe (SoftGenetics LLC, State College, PA).

All detected possibly disease-associated variants were confirmed by Sanger sequencing and analyzed with the Alamut software (http://www.interactive-biosoftware.com). Segregation of the variants with the disease was analyzed if family members were available. The allele frequencies of all variants were compared to the Exome Variant Server (EVS) dataset, NHLBI Exome Sequencing Project, Seattle, WA, USA (http://snp.gs.washington.edu/EVS/; accessed March 2014).

### 4.5. Statistics

The utilized statistical software was SPSS Statistics 16.0 for Windows (SPSS, Inc.; Chicago, IL, USA) and the data compared in the studies were deemed statistically significant when \( p < 0.05 \).

In Paper I, the statistical comparisons of the ELM and EZ measurements between study subjects and age-matched controls were done by unpaired Student t-tests (two-tailed). Agreement on manual measurements of the ELM and EZ was assessed between two independent observers with intraclass correlation coefficients (ICC).

The statistical comparison of the age at time of examination, age of onset and estimated disease duration between the p.G1961E and non-p.G1961E patients in Paper II was performed by unpaired Student t-test (two-tailed). Pearson’s chi-square test was used to analyze the significance of the presence of the p.G1961E allele in patients with the optical gap phenotype.

### 4.6. Ethics

All patients were enrolled in the study after consenting under the protocol #AAAI9906. The protocol was approved by the Institutional Review Board at Columbia University and adhered to the tenets set out in the Declaration of Helsinki. Each subject signed the informed consent.
5. RESULTS

5.1. Phenotypic expression and outer retinal abnormalities in young patients with STGD1 (Paper I)

The study cohort consisted of 26 young patients with early-onset STGD1 imaged before age 20 years.

5.1.1. Clinical and genetic evaluation of the young STGD1 patients

The mean disease duration was 3.2 years, ranging between 0.5 to 8 years. In 7 patients the data about disease duration was not available, because the patients did not remember the age when the symptoms started or the disease was detected accidentally. Best-corrected visual acuities ranged from 20/20 to 20/400 in both eyes. At least two (expected) disease-causing mutations in \textit{ABCA4} gene were identified in all patients, except one sibling pair (P2 and P3) and P20 in whom only one disease associated allele was found (Table 1).

5.1.2. Phenotypic evaluation of the young STGD1 patients

At the time of examination 54% of patients exhibited central macular atrophy with or without perifoveal flecks (Fishman stage 1), while 46% of patients exhibited more widespread flecks often extending anterior to the vascular arcades (Fishman stage 2). P12 presented asymptotically with no apparent changes on funduscopy and was discovered through an affected sibling. Eight patients (31%) presented with bull’s eye maculopathy phenotype. 18 patients (69%) patients presented either initially with, or eventually developed yellow pisciform flecks. Fundus autofluorescence imaging revealed the presence of “fine macular dots” in 14 patients (54%). Qualitative thickening of the ELM on SD-OCT was noted in all patients. Full-field ERG results were available for 19 patients, of which 13 (68%) exhibited normal generalized scotopic and photopic function (Group 1) and six (32%) had amplitudinal reduction and implicit time delays in the photopic system (Group 2). Patients were grouped into Group 1 or Group 2 accordingly (Lois et al., 2001).
Table 1. Summary of clinical and genetic characteristics of young STGD1 patients.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (y)</th>
<th>BCVA Snellen OD</th>
<th>BCVA Snellen OS</th>
<th>Fishman Stage</th>
<th>ffERG Group</th>
<th>Estimated Disease Duration, y†</th>
<th>ABCA4 Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Allele 1</td>
</tr>
<tr>
<td>P1</td>
<td>10</td>
<td>20/30</td>
<td>20/25</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>p.E160*</td>
</tr>
<tr>
<td>P2</td>
<td>10</td>
<td>20/70</td>
<td>20/80</td>
<td>2</td>
<td>2</td>
<td>0.5</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P3</td>
<td>7</td>
<td>20/40</td>
<td>20/30</td>
<td>1</td>
<td>ND</td>
<td>ND</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P4</td>
<td>13</td>
<td>20/80</td>
<td>20/50</td>
<td>2</td>
<td>1</td>
<td>ND</td>
<td>p.P1380L</td>
</tr>
<tr>
<td>P5</td>
<td>14</td>
<td>20/200</td>
<td>20/150</td>
<td>1</td>
<td>1</td>
<td>0.5</td>
<td>p.P1380L</td>
</tr>
<tr>
<td>P6</td>
<td>13</td>
<td>20/40</td>
<td>20/50</td>
<td>2</td>
<td>1</td>
<td>ND</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P7</td>
<td>8</td>
<td>n/a</td>
<td>n/a</td>
<td>1</td>
<td>n/a</td>
<td>ND</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P8</td>
<td>10</td>
<td>20/40</td>
<td>20/80</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>p.R1108C</td>
</tr>
<tr>
<td>P9</td>
<td>14</td>
<td>20/100</td>
<td>20/100</td>
<td>2</td>
<td>1</td>
<td>0.5</td>
<td>p.T972N</td>
</tr>
<tr>
<td>P10</td>
<td>9</td>
<td>20/150</td>
<td>20/400</td>
<td>2</td>
<td>1</td>
<td>ND</td>
<td>c.5312+1G&gt;A</td>
</tr>
<tr>
<td>P12</td>
<td>5</td>
<td>20/30</td>
<td>20/40</td>
<td>1</td>
<td>n/a</td>
<td>ND</td>
<td>c.5018+2T&gt;C</td>
</tr>
<tr>
<td>P13</td>
<td>10</td>
<td>20/200</td>
<td>20/200</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P14</td>
<td>12</td>
<td>20/200</td>
<td>20/200</td>
<td>2</td>
<td>2</td>
<td>6</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P15</td>
<td>16</td>
<td>20/200</td>
<td>20/200</td>
<td>2</td>
<td>n/a</td>
<td>8</td>
<td>p.K346T</td>
</tr>
<tr>
<td>P16</td>
<td>9</td>
<td>20/150</td>
<td>20/150</td>
<td>1</td>
<td>n/a</td>
<td>1</td>
<td>p.P1380L</td>
</tr>
<tr>
<td>P18</td>
<td>18</td>
<td>20/150</td>
<td>20/150</td>
<td>2</td>
<td>1</td>
<td>4</td>
<td>p.[L541P;A1038V]</td>
</tr>
<tr>
<td>P19</td>
<td>16</td>
<td>20/150</td>
<td>20/150</td>
<td>1</td>
<td>n/a</td>
<td>6</td>
<td>p.G863A</td>
</tr>
<tr>
<td>P20</td>
<td>18</td>
<td>20/125</td>
<td>20/50</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>p.R1640W</td>
</tr>
<tr>
<td>P21</td>
<td>12</td>
<td>20/50</td>
<td>20/50</td>
<td>1</td>
<td>1</td>
<td>6</td>
<td>p.W821R</td>
</tr>
<tr>
<td>P22</td>
<td>17</td>
<td>20/40</td>
<td>20/100</td>
<td>1</td>
<td>n/a</td>
<td>3</td>
<td>p.G1961E</td>
</tr>
<tr>
<td>P23</td>
<td>10</td>
<td>20/400</td>
<td>20/400</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>c.885delC</td>
</tr>
<tr>
<td>P24</td>
<td>19</td>
<td>20/20</td>
<td>20/20</td>
<td>1</td>
<td>n/a</td>
<td>ND</td>
<td>p.G863A</td>
</tr>
<tr>
<td>P26</td>
<td>17</td>
<td>20/150</td>
<td>20/200</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>p.K1547*</td>
</tr>
</tbody>
</table>

ND, not determined; n/a, not available.
† Estimated disease duration is defined as age of first examination minus reported age of onset.
5.1.3. Longitudinal changes in the cohort

Progression data following two or more time points, one year apart, revealed variable changes in each patient. Out of 17 patients who initially presented with yellow pisciform flecks, two (P2, P9) had very fast progression from small hyper-AF flecks around the fovea to partially resorbed flecks beyond the vascular arcades; two others (P11, P15) presented with larger hyper-AF flecks throughout the macula and developed flecks beyond the vascular arcades, exhibiting partial darkening and resorption of some flecks; and one (P8) appeared unaffected and developed small hyper-AF flecks around the fovea. Serial SD-OCT imaging revealed a receding EZ and apparent RPE thinning over time at the leading edge of the central lesion of atrophy. No apparent changes to the ELM were observed in this time period; however, a consistent discordance between the position of EZ loss and ELM loss was noted. In almost all observed cases, the EZ appeared to recede earlier than the ELM on SD-OCT.

5.1.4. Quantitative analysis of outer retinal layers in young STGD1 patients

The ELM and EZ thickness as well as reflectivity was measured and compared with the age-matched control subjects. The measurements of ELM and EZ thickness as well as reflectivity of the bands were done by two independent observers and the calculated ICCs revealed acceptable agreement between both observers for each measurement (Table 2).

<table>
<thead>
<tr>
<th></th>
<th>STGD1 Patients</th>
<th>Unaffected Individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sampled ELM Thickness (µm)</td>
<td>0.948 (0.782–0.982)</td>
<td>0.836 (0.659–0.922)</td>
</tr>
<tr>
<td>Sampled ELM Reflectivity (gray value)</td>
<td>0.938 (0.861–0.973)</td>
<td>0.920 (0.830–0.962)</td>
</tr>
<tr>
<td>Sampled EZ Thickness (µm)</td>
<td>0.796 (0.472–0.915)</td>
<td>0.874 (0.738–0.940)</td>
</tr>
<tr>
<td>Sampled EZ Reflectivity (gray value)</td>
<td>0.857 (0.675–0.937)</td>
<td>0.876 (0.736–0.941)</td>
</tr>
</tbody>
</table>

The 95% confidence intervals are in parentheses; SD-OCT, spectral domain-optical coherence tomography; ELM, external limiting membrane; EZ, ellipsoid zone; STGD1, Stargardt disease.

Qualitative and quantitative analyses of the ELM and EZ bands on SD-OCT revealed consistent and significant difference between STGD1 patients and age-matched controls. The thickness of the ELM band in the measured area was significantly greater (mean = 17.69 µm, SD = 4.23) in STGD1 patients, particularly in the three younger patients (P3, P10, P16), compared with unaffected individuals (mean = 11.45 µm, SD = 1.08, p < 0.0001; Table 3 and Figure 7, A). A mild downward trend in ELM thickness with age was noted (r² = 0.21), while ELM thickness appeared to be relatively constant in the control group.
We also measured the EZ thickness in the same area and detected that STGD1 patients exhibited a thinner (mean = 16.65 µm, SD = 2.34, \( p < 0.0001 \)) EZ compared with unaffected individuals (mean = 20.64 µm, SD = 1.34, \( p < 0.0001 \); Table 3 and Figure 7, B).

To assess the thickness of the ELM relative to the EZ, the calculated ratios of ELM/EZ in the patients were compared with the control ratios. Ratios of ELM/EZ in unaffected individuals fell consistently within the 0.5 range, indicating a 1-to-2 relationship between the thickness of the ELM and EZ on SD-OCT. Thickness ratios of ELM/EZ in STGD1 patients, while more variable, were significantly greater (\( p < 0.0001 \)) than the control group (Table 3 and Figure 7, C).

Band reflectance on SD-OCT was assessed by comparing the brightest pixel (vertical gray value profile peak) of the ELM and EZ bands (Table 3). To compare patients while accounting for scan normalization, reflectance values were compared as ratios for each patient. The reflectance ratios in STGD1 patients were significantly greater (\( p < 0.0001 \)) than those of the control group (Table 3 and Figure 7, D). Quantitation in two patients, P10 and P23, was impossible due to progressed atrophy in the measurement area; however, the ELM thickening and increased reflectivity was qualitatively observed in their respective SD-OCT scans in less-affected areas of the macula.

Table 3. Quantitative thickness and reflectivity sampling in SD-OCT scans.

<table>
<thead>
<tr>
<th>SD-OCT Thickness (µm)</th>
<th>SD-OCT Reflectivity (gray value)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean Measurements</strong></td>
<td><strong>SD-OCT Thickness</strong></td>
</tr>
<tr>
<td>EZ STGD1</td>
<td>EZ Control</td>
</tr>
<tr>
<td>Mean</td>
<td>16.65</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>2.34</td>
</tr>
<tr>
<td>Standard error</td>
<td>0.48</td>
</tr>
<tr>
<td>EZ STGD1</td>
<td>EZ Control</td>
</tr>
<tr>
<td>Mean</td>
<td>170.40</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>19.24</td>
</tr>
<tr>
<td>Standard error</td>
<td>3.98</td>
</tr>
</tbody>
</table>

**Unpaired \( t \)-test**

- EZ: STGD1 vs control: \( p < 0.0001 \)
- ELM: STGD1 vs control: \( p < 0.0001 \)
- ELM-EZ ratio: STGD1 vs control: \( p < 0.0001 \)

**SD-OCT Reflectivity**

- ELM-EZ ratio: STGD1 vs control: \( p < 0.0001 \)

SD-OCT, spectral-domain optical coherence tomography; ELM, external limiting membrane; EZ, ellipsoid zone; STGD1, Stargardt disease.
Figure 7. Quantitative analyses of the ELM and EZ band thickness and reflectivity on SD-OCT. Thickness (µm) of the ELM and EZ were measured at a consistent position within the macula in 24 STGD1 patients (red circles) and 30 age-matched controls (gray circles). Analysis of the designated area of the macula was not possible in two patients (P10, P23) due to progressed atrophy. (A) Thickness of the ELM in the measured areas was significantly greater \((p < 0.0001)\) in STGD1 patients compared with unaffected individuals, (B) whereas the thickness of the EZ at the same location was thinner in STGD1 \((p < 0.0001)\). (C) The relative ELM/EZ thickness (calculated as the ratio between the ELM and the EZ) within normal subjects consistently fell within 0.5 (EZ band is approximately two times thicker than the ELM band); an overall larger and more variable relative ELM/EZ thickness \((p < 0.0001)\) was observed in STGD1 patients. (D) Relative reflectivities of the ELM-to-EZ bands where significantly more intense \((p < 0.0001)\) in STGD1 patients compared with normal controls.

5.2. Optical gap phenotype in STGD1 (Paper II)

The optical gap, also referred as optically empty lesion or foveal cavitation (Leng et al., 2012), is a retinal phenotype representing a focal loss of subfoveal photoreceptors detectable on SD-OCT as a focal loss of ellipsoid reflectivity leaving an optically empty space under the fovea (Leng et al., 2012).

We detected the optical gap phenotype in 15 STGD1 patients from the cohort of 179 patients with the available SD-OCT images and characterized the optical gap phenotype in STGD1 according to its developmental stages. We investigated the mutations in the \(ABCA4\) gene in these patients and detected a phenotype-genotype association.
5.2.1. Clinical and phenotypic evaluation of STGD1 patients with the optical gap phenotype

Fifteen patients were detected and evaluated from a cohort of 179 patients (Table 4). The mean age of the patients with the optical gap phenotype was 23.5 years (range, 12–30 years) and the reported age of the disease onset was in the second and third decades of life (mean age of onset of 19.4 years) corresponding to the mean symptomatic disease duration of 4 years. One patient (P1) was asymptomatic at the time of presentation.

Thirteen patients exhibited a bull’s eye-like phenotype on color fundus photos. Parafoveal flecks were observed in 6 patients (12 eyes). Fixation was assessed at the first visit in 10 patients. Eighteen eyes from 10 patients had extrafoveal fixation, while P10 and P11 had preserved central fixation in the right eye only due to the eccentric localization of the optical gap and preserved ellipsoid zone in the center.

All except two patients (P1, P2) had undergone full-field ERG at initial visit and were categorized to Group 1 (Lois et al., 2001) having age-matched normal scotopic and maximal responses. Multifocal ERG data were available in six patients, while half of them had data available only for the right eye. Each patient had decreased responses in the central 5° to 15° on mf ERG, showing much larger affected area than SD-OCT and FAF images predicted.

5.2.2. Structural staging of the optical gap phenotype with SD-OCT

Based on clinical observation and follow-up data from SD-OCT images we staged the optical gap phenotype and divided the patients into three disease development groups (Figure 8).

Stage 1: Moderate ellipsoid zone disruptions.

The initial stage represented distinctive structural breaks in the EZ and degradation of photoreceptors in the foveal outer retina on SD-OCT forming an optically empty zone fulfilled with remnants of the ellipsoid (Figure 8, P2). The ONL thinning in the macula was present in all patients, while the ELM and the RPE were intact. Five patients (10 eyes) of the 15 patients presented with this, Stage 1, disease.

Best corrected visual acuity was relatively mildly affected ranging from 20/25 to 20/60 (mean 20/40) and appeared to be dependent on the degree of EZ band loss.

Fundus autofluorescence images showed a dark roundish lesion with reduced FAF signal in 4 patients, while one patient exhibited a more horizontally-elongated lesion.
<table>
<thead>
<tr>
<th>Patient #, Gender</th>
<th>Age (yrs)</th>
<th>BCVA Snellen OD</th>
<th>BCVA Snellen OS</th>
<th>Age of Onset (yrs)</th>
<th>Optical Gap Staging Initial OD</th>
<th>Optical Gap Staging Current OD</th>
<th>Optical Gap Staging Current OS</th>
<th>ERG Group</th>
<th>Lesion shape on AF</th>
<th>Fixation</th>
<th>Fixation</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>22</td>
<td>20/40</td>
<td>20/50</td>
<td>Unknown</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>25</td>
<td>20/40</td>
<td>20/30</td>
<td>24</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>30</td>
<td>20/30</td>
<td>20/30</td>
<td>25</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>G1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>30</td>
<td>20/25</td>
<td>20/25</td>
<td>25</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>G1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>18</td>
<td>20/60</td>
<td>20/60</td>
<td>14</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>G1</td>
<td>Eccentric</td>
<td>Eccentric</td>
</tr>
<tr>
<td>F</td>
<td>24</td>
<td>20/150</td>
<td>20/150</td>
<td>14</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>22</td>
<td>20/100</td>
<td>20/100</td>
<td>17</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1 Speckled</td>
<td>Eccentric</td>
<td>N/A</td>
</tr>
<tr>
<td>F</td>
<td>19</td>
<td>20/80</td>
<td>20/80</td>
<td>15</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td>Eccentric</td>
<td>Eccentric</td>
</tr>
<tr>
<td>F</td>
<td>25</td>
<td>20/100</td>
<td>20/150</td>
<td>15</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td>Eccentric</td>
<td>Eccentric</td>
</tr>
<tr>
<td>F</td>
<td>23</td>
<td>20/40</td>
<td>20/30</td>
<td>18</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td>Eccentric</td>
<td>Foveal</td>
</tr>
<tr>
<td>M</td>
<td>23</td>
<td>20/40</td>
<td>20/30</td>
<td>22</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>22</td>
<td>20/50</td>
<td>20/70</td>
<td>21</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td>12</td>
<td>20/50</td>
<td>20/50</td>
<td>10</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>G1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>30</td>
<td>20/100</td>
<td>20/100</td>
<td>25 Atrophy</td>
<td>2</td>
<td>Atrophy</td>
<td>3</td>
<td>G1 +*</td>
<td>Eccentric</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>28</td>
<td>20/30</td>
<td>20/30</td>
<td>26</td>
<td>3</td>
<td>3</td>
<td>Atrophy</td>
<td>Atrophy</td>
<td>G1</td>
<td>Eccentric</td>
<td>Eccentric</td>
</tr>
</tbody>
</table>

F, female; M, male; N/A, not available.

* left eye only.
Stage 2: Expanded foveal cavitation.
A widened empty cavity characterized by total absence of the EZ was observed on SD-OCT in eight patients (Figure 8, P12). Some granular deposits or residual debris were attached to the concavely arched ELM in the lesion. A relatively larger, horizontally-elongated lesion resembling an elliptical bull’s eye lesion within a hyper-AF halo was observed on FAF imaging in six patients, while P6 had speckled macular appearance on FAF image, which corresponded with fleck-like deposits in the central macula.

Mean visual acuity in Stage 2 patients was 20/80 spanning a spectrum from 20/30 to 20/150. In two patients (P10, P11) the optical gap lesion was atypically eccentrically off-centered, preserving the EZ at the fixation point. Therefore, these patients maintained the BCVA of 20/40 and 20/30 in the right and left eyes, respectively and central fixation in the right eye.

Stage 3: Inner retinal collapse.
A structural collapse of the inner retinal layers into the vacant ellipsoid space with residual spaces along the edge of the previously occupied gap lesion was observed in P14 (Figure 8, P14), where we had clear evidence on OCT images showing transition from stage 2 to stage 3. In the retrospective review of the whole cohort, we detected another patient with similar structure with the residual gap spaces along the edges of the lesion, P15.
Visual acuities appeared similar to stage 2 patients, while the BCVA of P15 was relatively preserved at 20/30 in both eyes, possibly explained by relatively spared outer retina fragment in the foveal center seen on FAF and SD-OCT images.

5.2.3. Longitudinal analysis of the optical gap phenotype in STGD1

The longitudinal data enabled us to understand how the optical gap structure behaves over the time and made possible to create the staging system for the optical gap phenotype.

Longitudinal data and images were available and analyzed in 8 patients (P5-P8 and P12-P15). The initial and current stage is presented in Table 4.

Inter-stage progression was observed in patients P5, P14 and P15, while other patients for whom the data were available remained Stage 2 within 1.5 to 3 years follow-up (Figure 9). P5 initially presented with mild photoreceptor disorganization and Stage 1 optical gap was detected after one year. The BCVA progressed from 20/30 and 20/25 to 20/60 in both eyes. Her older sibling (P6) exhibited a more advanced Stage 2 optical gap lesion. P14 progressed from Stage 2 to Stage 3 within 2 years retaining a stable BCVA of 20/100 in both eyes. Progression of Stage 3 gap to progressive atrophy within 1 year was seen in P15.

**Figure 9.** Gantt chart summarizing the ABCA4-associated optical gap stage progression and duration. Longitudinal OCT imaging was available for eight patients in the study cohort. Patient 5 presented with minor EZ changes (Stage 0) and progressed bilaterally to Stage 1 optical gap a year after initial examination. Patients 6, 7, 8, 12 and 13 initially presented and remained in Stage 2 over a range of 1.5 to 3 years. Patients 15 progressed to an atrophic stage following Stage 3, while P14 exhibited unilateral progression from Stage 2 to Stage 3 in the left eye.

42
5.2.4. Phenotype-genotype association in STGD1 with the optical gap phenotype

The cohort of 15 patients included 11 unrelated cases and four sibling pairs. Segregation analysis was available for 11 patients. At least two (expected) disease-causing variants were identified in each patient. In unrelated cases, 91% were compound heterozygous for the p.G1961E variant (Table 5). With the exception of P13, the optical gap was not observed in the SD-OCT scans of any other non-p.G1961E patients (n = 131) whose age at time of examination, age of onset and estimated disease duration were not statistically different from those of p.G1961E (n = 48) patients (Table 6). The allele frequency of p.G1961E allele in patients with the optical gap phenotype was 46.7%, while in the entire STGD1 cohort of 179 patients (157 unrelated individuals) it was 13.4%, showing statistically highly significant difference (p < 0.0001).

Table 5. Summary of genetic data of ABCA4-associated optical gap patients.

<table>
<thead>
<tr>
<th>Patient #, Gender</th>
<th>DNA level</th>
<th>Protein level</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, F†*</td>
<td>c.[286A&gt;G];[5882G&gt;A]</td>
<td>p.[(N96D)];[(G1961E)]</td>
</tr>
<tr>
<td>P2, F†*</td>
<td>c.[286A&gt;G];[5882G&gt;A]</td>
<td>p.[(N96D)];[(G1961E)]</td>
</tr>
<tr>
<td>P3, M†</td>
<td>c.[1622T&gt;C(;)3113C&gt;T(;5882G&gt;A]</td>
<td>p.[(L541P(;)A1038V(;G1961E)]</td>
</tr>
<tr>
<td>P4, M†</td>
<td>c.[1622T&gt;C(;)3113C&gt;T(;5882G&gt;A]</td>
<td>p.[(L541P(;)A1038V(;G1961E)]</td>
</tr>
<tr>
<td>P5, F†*</td>
<td>c.[1622T&gt;C(;)3113C&gt;T(;5882G&gt;A]</td>
<td>p.[(L541P(;)A1038V(;G1961E)]</td>
</tr>
<tr>
<td>P6, F†*</td>
<td>c.[1622T&gt;C(;)3113C&gt;T(;5882G&gt;A]</td>
<td>p.[(L541P(;)A1038V(;G1961E)]</td>
</tr>
<tr>
<td>P7, F†*</td>
<td>c.[1622T&gt;C(;5882G&gt;A]</td>
<td>p.[(L541P)];[(G1961E)]</td>
</tr>
<tr>
<td>P8, F†*</td>
<td>c.[1622T&gt;C(;5882G&gt;A]</td>
<td>p.[(L541P)];[(G1961E)]</td>
</tr>
<tr>
<td>P9, F*</td>
<td>c.[5882G&gt;A];[6448T&gt;C]</td>
<td>p.[(G1961E)];[(C2150R)]</td>
</tr>
<tr>
<td>P10, F*</td>
<td>c.[4139C&gt;T(;5882G&gt;A]</td>
<td>p.[(P1380L)];[(G1961E)]</td>
</tr>
<tr>
<td>P11, M</td>
<td>c.[5318C&gt;T(;5882G&gt;A]</td>
<td>p.[(A1773V(;)G1961E)]</td>
</tr>
<tr>
<td>P12, F*</td>
<td>c.[5196+1056A&gt;G];[5882G&gt;A]</td>
<td>p.[?];[(G1961E)]</td>
</tr>
<tr>
<td>P13, M*</td>
<td>c.[2461T&gt;A(;)6449G&gt;A]</td>
<td>p.[(W821R)];[(C2150Y)]</td>
</tr>
<tr>
<td>P14, F</td>
<td>c.[5882G&gt;A];[6229C&gt;T]</td>
<td>p.[(G1961E(;)R2077W)]</td>
</tr>
<tr>
<td>P15, F*</td>
<td>c.[1622T&gt;C(;)4328G&gt;A];[5882G&gt;A]</td>
<td>p.[(L541P;R1443H)];[(G1961E)]</td>
</tr>
</tbody>
</table>

†Sibling pairs: P1 and P2, P3 and P4, P5 and P6, P7 and P8.
*The variants are confirmed on different chromosomes.

<table>
<thead>
<tr>
<th>Clinical data</th>
<th>p.G1961E mutation(s) n: 48</th>
<th>Other ABCA4 mutations n: 131</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>Mean 34.5 SD 18.6 Median 28.5 Range 5 to 78</td>
<td>Mean 36.9 SD 17.8 Median 37.6 Range 7 to 83</td>
<td>&gt; 0.4</td>
</tr>
<tr>
<td><strong>Age of Onset</strong></td>
<td>Mean 20 SD 10.1 Median 17.5 Range 2 to 55</td>
<td>Mean 19.4 SD 12.1 Median 16.5 Range 4 to 52</td>
<td>&gt; 0.7</td>
</tr>
<tr>
<td><strong>Disease Duration</strong></td>
<td>Mean 15.6 SD 17.8 Median 8.5 Range 0.1 to 71</td>
<td>Mean 17.8 SD 14.9 Median 14.3 Range 0.2 to 63</td>
<td>&gt; 0.4</td>
</tr>
</tbody>
</table>

Other than bull’s eye lesion (minor macular changes to more advanced atrophy).

5.3. A subtype of foveal sparing phenotype in STGD1 resembling HCQ retinopathy (Paper III)

We detected and analyzed 8 unrelated patients with STGD1 from the cohort of 200 STGD1 patients who exhibited a variant of foveal sparing phenotype on SD-OCT described previously with HCQ retinopathy. This transient HCQ retinopathy SD-OCT phenotype represents an outer retinal thinning in the parafoveal region with the relative sparing of the foveal region, colloquially termed the „flying saucer“ sign (Chen et al., 2010). A retrospective clinical and genetic evaluation of these patients was done and structural analysis of the retina was carried out. Three patients with STGD1 were having classical bull’s eye lesion similar to HCQ retinopathy.

5.3.1. Clinical and genetic evaluation of the patients

The cohort (age range, 10–57 years) consisted of ethnically diverse individuals who presented to the Retina Clinic for a retinal evaluation. All patients presented to the clinic without a medical history of HCQ use (Table 7). Five patients (P2, P4, P5, P6 and P7) reported no visual symptoms but were referred for a retinal evaluation after routine optometric visits, while P3 complained of mild bilateral
metamorphopsia and P8 complained of halos in front of both eyes. The majority of the patients had 20/20 vision (Table 7). Full-field ERG results showed no generalized rod or cone dysfunction.

Genetic screening of both the \textit{ABCA4} and \textit{PRPH2} genes by complete sequencing of the coding regions confirmed two (expected) disease-causing \textit{ABCA4} mutations in five patients and one mutation in the remaining three patients. No mutations in the \textit{PRPH2} gene were found.

\textbf{Table 7. Clinical and genetics characteristics of the study cohort.}

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, Gender</th>
<th>Snellen BCVA</th>
<th>Fundus Appearance</th>
<th>\textit{ABCA4} Mutation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>53, M</td>
<td>20/20</td>
<td>Mottling + Flecks</td>
<td>c.[5461-10T&gt;C]</td>
</tr>
<tr>
<td>P3</td>
<td>57, M</td>
<td>20/20</td>
<td>BEM + Flecks</td>
<td>p. [R2107H]</td>
</tr>
<tr>
<td>P4</td>
<td>10, F</td>
<td>20/30</td>
<td>BEM + Flecks</td>
<td>p. [E160*]; [R1108C]</td>
</tr>
<tr>
<td>P5</td>
<td>26, F</td>
<td>20/30</td>
<td>Mottling + Flecks</td>
<td>p. [R2107H]; [E526A]</td>
</tr>
<tr>
<td>P6</td>
<td>19, F</td>
<td>20/25</td>
<td>BEM</td>
<td>p. [R602W]</td>
</tr>
<tr>
<td>P7</td>
<td>26, M</td>
<td>20/20</td>
<td>BEM</td>
<td>p. [R1300*]; [R2106C]</td>
</tr>
<tr>
<td>P8</td>
<td>25, M</td>
<td>20/20</td>
<td>BEM</td>
<td>p. [Q1003*]; [G1961E]</td>
</tr>
</tbody>
</table>

M, male; F, female; BCVA, best-corrected visual acuity; OD, right eye; OS, left eye; BEM, bull’s eye maculopathy.

\subsection*{5.3.2. Structural analysis of the retina}

\textbf{Fundus photos and FAF imaging}

All patients exhibited either a confined or bull’s eye maculopathy (BEM)-type lesion restricted within the vascular arcades on fundus photos (Figures 10 and 11). Yellow fleck deposits around the central lesions were observed in five patients (P1–5). Accompanying macular lesions in FAF imaging varied among patients. Round or elliptical BEM lesions with a dark center and hyper-AF border were noted in P6, P7 and P8, while mottled fleck patterns where observed in P1–5 (Figures 10 and 11). Patients 3 and 4 also exhibited a ring of fluorescent granular deposits surrounding the hypo-AF ovoid foveal lesion (Figures 10 and 11, P3 and P4).
Structural analysis of the retina on SD-OCT

Single horizontal line scans through the fovea and volume SD-OCT scans in each patient revealed an abrupt disruption of the EZ band in the parafoveal region and thinning of the outer nuclear layer (ONL), with relative sparing of the central foveal region. Posterior displacement of the parafoveal inner retinal layers and relatively spared fovea with slightly anteriorly bowing ELM and EZ bands forming a so-called „flying saucer“ configuration associated with HCQ-induced retinal toxicity was evident in all patients (see Figures 10 and 11).

Despite the apparent sparing of the fovea, SD-OCT scans showed some abnormalities within this region in all patients. All patients had loss of the IZ and thinning of ONL and EZ, except P3, who exhibited normal apparent thickness of all retinal layers, and P1, who showed no apparent decrease in ONL thickness in the fovea (Figures 10 and 11). Thinning of the RPE-Bruch’s membrane complex in the fovea was observed in three patients (P2, P7 and P8). Patient 4 exhibited a thickened ELM protuberance that delimited a thin layer of spared EZ in the fovea.

The degree of outer retina involvement in the parafoveal region was variable. Three patients (P1–3) showed discontinuity/disruption of the EZ band and thinning of ONL preserving the ELM. Ellipsoid zone disruption in P1 was seen throughout a speckled FAF lesion. Total loss of parafoveal EZ was seen in P4–8, while P7 and P8 had the most prominent changes, resembling most advanced parafoveal atrophy with the ELM loss and the RPE thinning (Figure 11, P7 and P8). The RPE thinning in this region also was noted in P1 and P2, while P2 had a very confined area of geographic atrophy in the nasal side of the fovea (Figure 10, P2). Interdigitation zone loss was present in all patients, becoming visible in parafoveal region in three patients (P2, P7 and P8).

5.3.3. Lesion formation

A preceding stage of the transient HCQ retinopathy phenotype in STGD1 was observed in P6, who exhibited EZ band loss (optically empty space) in the parafoveal region around the central island of preserved and hyper-reflective photoreceptor layer (Figure 12, c). Seven months later, the optically empty space appeared to collapse, forming a lesion resembling the transient HCQ-induced retinal toxicity SD-OCT phenotype (Figure 12, f)
Figure 10. Thinning of the parafoveal region with relative foveal sparing presenting as the hydroxychloroquine retinopathy associated parafoveal outer retina thinning phenotype in patients with Stargardt disease. Color photograph (a), fundus autofluorescence (b), and spectral-domain optical coherence tomography (c) images of an unaffected individual with outer retinal layers defined: the outer nuclear layer (ONL), the external limiting membrane (ELM), the ellipsoid zone (EZ), the interdigitation zone (IZ) and the retinal pigment epithelium (RPE) (Inset). Yellow pisciform flecks accompanying mottling over in the central macula are apparent on color, FAF and SD-OCT (g, h, i; red arrows). Corresponding SD-OCT scans (f, i, l) reveal abrupt disruptions of the outer retinal layers in the parafoveal regions in each patient (white arrows).
Figure 11. Abrupt thinning of the parafoveal region (white arrows), with relative foveal sparing, presenting as the hydroxychloroquine retinopathy associated parafoveal outer retina thinning phenotype with Stargardt disease, continued. Color photographs (a, d, g, j), fundus autofluorescence images (b, e, h, k, n), and spectral-domain optical coherence tomography images (c, f, i, l, o) in patients 4, 5, 6, 7 and 8; infrared reflectance image (m) in P8.
Figure 12. Structural development of a lesion resembling the HCQ associated parafoveal outer retina thinning phenotype in patient 6. Color (a) and autofluorescence (b) images presented with corresponding spectral domain-optical coherence tomography scans in both eyes (c). Parafoveal optically empty lesions in each eye (dotted box) are apparent bilaterally. A subsequent visit 7 months later (d, e, f) revealed an apparent collapse of the inner retinal layers forming abrupt thinning of the parafoveal region (white arrows), consistent with an HCQ-induced retinal toxicity presentation.
6. DISCUSSION

STGD1 is the most common inherited macular dystrophy caused by defective ABCA4 transporter leading to excessive lipofuscin accumulation, RPE cell and photoreceptor degeneration (Molday and Zhang, 2010). The classical phenotype in STGD1 is an atrophic-appearing macular lesion with pisciform yellowish flecks, but there is a remarkable phenotypic heterogeneity (Michaelides et al., 2003).

Today, the modern imaging methods provide us with new possibilities in studying the phenotypic expression of the disease (Keane and Sadda, 2014). One of such is SD-OCT, which enables to perform in vivo histology and detect even very fine structural changes in the retina.

All our studies used SD-OCT to assess the retinal structural changes and phenotypes in STGD1. The universal phenotypic feature in STGD1 is outer retinal degeneration and thinning detectable on SD-OCT (Duncker et al., 2014, Burke et al., 2011, Park et al., 2015, Ergun et al., 2005), however it has been shown that inner retinal changes accompany with photoreceptor loss indicating that retina is a complex tissue with different cell types and communications (Huang et al., 2014, Genead et al., 2011, Pasadhika et al., 2009).

6.1. Early stage retinal structural changes in STGD1

We have shown for the first time quantitatively in a cohort of patients that, in addition to atrophic outer retinal changes, there is an abnormal ELM thickening in young STGD1 patients. At the time of the study (Paper I) we found only 2 case reports in the literature mentioning the ELM thickening in patients with STGD1 (Burke et al., 2013, Fujinami et al., 2014). One of them reported a single case of a young patient with STGD1 exhibiting an unusual thickening of the ELM on SD-OCT in the absence of other functional and structural changes in the retina (Burke et al., 2013).

Our study included 26 young (< 20 years old) STGD1 patients, imaged relatively soon after the disease onset, and 30 age-matched controls. The quantitative analysis revealed that all patients, except two in whom quantitation was not possible, exhibited significantly thicker and hyper-reflective ELM but thinner EZ compared with the control individuals. The EZ thinning, representing photoreceptor abnormalities (Spaide and Curcio, 2011, Wong et al., 2012), was expected considering the pathogenesis of the disease, while the ELM thickening was somewhat surprising.

The exact source of band reflectivity on SD-OCT is largely unknown, but it has been suggested that mitochondria may partly contribute to the OCT visibility, among other structures. Ellipsoid zone represents the ellipsoids of photoreceptor inner segments, containing high volume of mitochondria (Spaide and Curcio, 2011). The band has been shown to correlate well with the health of photoreceptors and the visual function (Wong et al., 2012, Testa et al., 2012,
while the hyper-reflective band above EZ is thought to represent the ELM, which is formed by the apical ends of Müller cells forming junctional complexes between each other and photoreceptors (Spaide and Curcio, 2011, Staurenghi et al., 2014, Ross and Pawlina, 2011). Therefore, several hypotheses can be generated from these findings. First, changes in the ELM can be attributed to the (mis)interaction between photoreceptors and Müller cell processes or homotypically between Müller cells (Burke et al., 2013). Secondly, it has been hypothesized that the ELM thickening and higher reflectivity could be caused by the mitochondria translocation and attachment to the ELM in the background of retinal degeneration (Litts et al., 2015).

Müller cells became reactive to many pathologic stimuli in the retina-weather extrinsic or intrinsic. In the background of photoreceptor degeneration and possible neuroinflammation (Radu et al., 2011, Kohno et al., 2013, Zhou et al., 2006) Müller cell activation is vital, protecting the surrounding neurons and restoring homeostasis in the retina via various mechanisms, including secretion of neurotropic factors, growth factors and cytokines (Reichenbach and Bringmann, 2013). Müller cell activation leads to their reactive gliosis (Bringmann et al., 2009, Bringmann et al., 2006), which involves hypertrophy, proliferation and migration of the glial cells and their processes (Bringmann et al., 2009, Vecino et al., 2016). It is known, that retinal degeneration does not cause only photoreceptor and RPE death, but the process is much more complex and certain pattern of retinal remodeling takes place, including glial seal formation composed of Müller cell distal processes (Jones and Marc, 2005). However, there are still limited data on Müller cell gliosis in retinal dystrophies. In STGD1 we found only one histopathological study on two enucleated eyes, which described the reactive Müller cell hypertrophy in addition to reduced number of photoreceptors and the RPE cells (Birnbach et al., 1994). However, some other in vivo studies with mammals have demonstrated early Müller cell activation and gliosis in retinitis pigmentosa models. In retinitis pigmentosa RPE65 mutant dog model, transient Müller cell activation was noted, interestingly more intense in early stages and younger animals possibly due to less advanced degenerative changes (Vecino et al., 2016). Retinitis pigmentosa P23H (rhodopsin) rat model shows hypertrophy of both Müller cells and astroglia indicating to reactive gliosis in the retina (Fernandez-Sanchez et al., 2015). The hypertrophic Müller cell apical ends form firework-like structures into the ONL, which disappeared in later stages of retinal degeneration (Fernandez-Sanchez et al., 2015). All this indicates that the reactive response is probably a transient event in a background of less advanced atrophic changes. The same is supported by our clinical observation that the ELM prominence is noted in younger patients with generally less advanced atrophic changes. Furthermore, we found the ELM prominence gradually decrease with increasing patient age (downward sloping trend line, $r^2 = 0.21$).

Whether the extensive ELM thickening detectable on SD-OCT is specific to STGD1 needs to be investigated further, but existing studies show that despite
the universal reactive gliosis in retinal stress situations, the extent of the process is disease specific (Hippert et al., 2015).

Different retinal dystrophies share common cellular responses to stress, such as inflammatory response, oxidative stress and activation of apoptotic pathways (Cuenca et al., 2014), but each has also specific factors depending on the etiology and pathogenesis. These include rate of cell loss, intercellular interactions or local change in the chemical milieu which all may affect Müller cell responses. In STGD1 the characteristic pathologic event is increased lipofuscin accumulation, which may contribute to the ELM prominence, furthermore very recently the ELM thickening as an early stage abnormality was described in another Stargardt-like lipofuscin-associated retinopathy (Palejwala et al., 2016).

The study has some limitations. The quantitation method, including the spatially restricted area of the measurements, image quality, inter subject scan normalization, among others, is likely to introduce errors, further necessitating more extensive analyses in addition to those that have been previously described (Hood et al., 2011, Hood et al., 2009). However, comparable studies have confirmed the reproducibility of SD-OCT measurements with built-in caliber tool from the instrument (Heidelberg Engineering) used in this study (Yamashita et al., 2012). In addition, we calculated the intraclass correlation coefficients for the measurements, which showed acceptable agreement between two independent measurers, further indicating compatibility.

It has to be noted, that the patient age was strictly confined to < 20 years. Presuming that ELM abnormalities occur in early stages of STGD1, we examined a cohort of 26 clinically diagnosed and genetically confirmed patients soon after the disease onset. Symptomatic changes indicative of early-onset STGD1 typically begin within the first and second decades of life (Michaelides et al., 2003). Therefore, the inclusion criteria were limited to those patients first examined when aged younger than 20 years. At the time of imaging, most of the patients in our cohort had relatively early stage of the disease (Fishman 1 (54%) or 2 (46%)) with the mean disease duration of 3.2 years. Therefore, due to our selection criteria, we cannot extend these findings to the later-onset disease.

6.2. Sub-phenotypes in STGD1 detectable on SD-OCT

Optical gap phenotype in STGD1

There are several sub-phenotypes in STGD1 which are best detected on SD-OCT, one of which is the optical gap phenotype. It represents a focal loss of subfoveal photoreceptors leaving an optically empty space detectable by SD-OCT (Leng et al., 2012, Cella et al., 2009). The phenotype has been associated with retinal dystrophies mostly affecting cone photoreceptors, such as rod monochromatism (Greenberg et al., 2014) and maculopathies caused by mutations in RP1L1 and KCNV2 genes (Park et al., 2010, Sergouniotis et al., 2012). In the literature, only sporadic cases of the optical gap phenotype in
STGD1 have been published (Cella et al., 2009, Leng et al., 2012, Gomes et al., 2009, Ritter et al., 2013).

We conducted a study (Paper II), specifically looking for the optical gap phenotype in a large cohort of STGD1 patients to assess the structural development, possibly deciphering the early effects of ABCA4 dysfunction in this phenotypic subgroup, and the genetic background of the phenotype. Furthermore, we were interested in the association between the phenotype and the retinal function.

The analysis of this patient cohort suggests that the development of optical gap can be divided into three structural stages over several years. Stage 1 patients present with disorganization of photoreceptors and intermittent brakes in the EZ band forming gap lesion in the subfoveal region. A further spatial depletion of the EZ is seen in Stage 2 patients where an expansive subfoveal empty cavity is apparent with accompanying decline in visual acuity. Stage 3 represents a structural collapse of the inner retina into the gap lesion. The visibility of the EZ band has been attributed to the photoreceptor integrity correlating well with visual function (Wong et al., 2012, Testa et al., 2012), therefore patients with Stage 1 optical gap had relatively spared central vision, compared with patients exhibiting more severe EZ loss in Stages 2 and 3. All patients with the optical gap phenotype and available fERG recordings had normal full-field ERG findings indicating a localized disease and better prognosis in terms of visual function (Fujinami et al., 2013a, Zahid et al., 2013, Lois et al., 1999).

Loss of ABCA4 function results in lipofuscin deposition in the RPE cells that have phototoxic effects on the RPE cells ultimately leading to its imminent death (Sparrow et al., 2000, Sparrow and Boulton, 2005). This mechanism supports the current understanding that structural degeneration of the RPE cells sequentially precedes that of photoreceptors in STGD1 (Sparrow and Boulton, 2005, Cideciyan et al., 2004, Glazer and Dryja, 2002). However, there are still some controversies in the understanding of exact sequence of disease process (Gomes et al., 2009, Duncker et al., 2014, Chen et al., 2011, Song et al., 2015, Glazer and Dryja, 2002). In addition to observation by other groups (Gomes et al., 2009, Cella et al., 2009, Leng et al., 2012), our study supports the finding that the photoreceptors degeneration precedes RPE death in this subgroup of patients. First of all, in Stages 1 and 2 the RPE seems relatively intact despite the EZ band disruption. Secondly, the mfERG from nine eyes showed decreased responses in the 5° to 15° of retina in the posterior pole. Similar to other mfERG studies in STGD1 (Kretschmann et al., 1998, Gomes et al., 2009) the functionally affected areas were much larger than structural changes on SD-OCT or FAF, suggesting that functional loss precedes structural changes in these patients. Additionally, given that the decreases in mfERG responses have been attributed to the influence of the EZ band, a case can be made for early photoreceptor dysfunction preceding structural RPE loss in these patients (Testa et al., 2012, Gomes et al., 2009). This is further supported by the genetic background of the phenotype. We detected that the optical gap phenotype is associated with the
p.G1961E allele. The p.G1961E allele in homozygous or compound heterozygous state has been associated with a milder, localized disease process that is confined to the central macula, often as a bull’s eye lesion, in conjunction with a characteristic absence of “dark choroid” on fluorescein angiography (Fishman et al., 1999, Cella et al., 2009, Simonelli et al., 2005). The absence of “dark choroid” reflects lower levels of lipofuscin accumulation, which was further demonstrated with quantitative autofluorescence imaging, showing that FAF levels are much lower in STGD1 patients carrying the p.G1961E allele compared to non-p.G1961E STGD1 patients (Burke et al., 2014). Low lipofuscin levels imply that cone dysfunction probably precedes RPE lipofuscin toxicity in the central maculae of p.G1961E patients indicating that a different pathogenetic mechanism compared to other STGD1 patients is possible (Burke et al., 2014).

Furthermore, there is increasing evidence that free all-trans retinal causes light-induced photoreceptor degeneration directly even without the presence of A2E (Maeda et al., 2009, Maeda et al., 2012, Chen et al., 2012, Maeda et al., 2014), therefore this pathogenic mechanism probably predominates in this subgroup of STGD1 patients. Our results of the structural behavior and the discussion of disease sequence were further supported by the findings from Sisk et al (Sisk and Leng, 2014), who published their study about the same time as we did, however their cohort was based on opthalmoscopic findings and, in our opinion, contained only two patients with an evident optical gap phenotype.

A subtype of foveal sparing phenotype in STGD1

Another phenotype in STGD1 is foveal sparing, best detectable by SD-OCT. In contrast to the optical gap phenotype, where early foveal cone involvement takes place, foveal sparing phenotype on the contrary exhibits a relatively intact fovea, preserving cones and good visual function (van Huet et al., 2014, Fujinami et al., 2013d). We detected a variant of foveal sparing phenotype in STGD1 associated mostly with HCQ retinopathy. The phenotype is described as a thinning of the outer retinal layers around the preserved region of the ellipsoid zone forming “flying saucer” configuration. Therefore, the phenotype is colloquially called a “flying saucer” sign in HCQ retinopathy (Chen et al., 2010, Marmor, 2012, Ascaso et al., 2013, Tailor et al., 2012).

We detected 8 STGD1 patients with similar SD-OCT phenotype, 3 of whom exhibited also HCQ retinopathy-like BEM lesions on FAF and funduscopy, showing that Stargardt disease may phenocopy the HCQ retinopathy (Paper III). The majority of the patients did not report any visual symptoms and had excellent visual acuity, which is consistent with the relatively spared fovea with intact photoreceptors. Our study confirmed that despite similarities in SD-OCT imaging in these patients, a valuable imaging tool in differentiating STGD1 from HCQ retinopathy is FAF, because most of the patients exhibit characteristic flecks, although not always, as 3 patients revealed classical BEM lesion, without any apparent hyper-AF flecks.
Spectral-domain OCT revealed variable severity of retinal atrophy in the parafoveal region, while five younger patients (P4–8) showed also qualitatively thickened and hyper-reflective ELM, in consistent with the first study (Paper I), while in 3 older patients the prominence was not that obvious, indicating to the importance of this finding in younger STGD1 patients. Based on our clinical observation the ELM prominence is not evident in HCQ retinopathy, but it has to be noted that patients with HCQ toxic maculopathy are generally older. Furthermore, despite the relatively spared fovea in these STGD1 patients, all patients had the loss of IZ and majority exhibited some degree of ONL thinning uncommon in an early or moderate stage of HCQ retinopathy (Marmor, 2012).

The development of the HCQ retinopathy-like SD-OCT phenotype was noted in one patient, where similar optically empty lesion as described in Paper 2 formed around a central island of preserved photoreceptors later collapsing and leaving a phenotype resembling the HCQ retinopathy.

The exact mechanism of HCQ retinal toxicity is not fully understood, however both, STGD1 and HCQ, share some common mechanistic features. It has been shown that HCQ may cause lysosomal dysfunction leading to lipofuscin accumulation (Mahon et al., 2004, Sundelin and Terman, 2002), while STGD1 is caused by a defective ABCA4 transporter, which similarly leads to lipofuscin accumulation (Molday and Zhang, 2010). The lipofuscin is toxic to the RPE cells and photoreceptors, leading to the outer retinal degeneration (Sparrow et al., 2000, Sparrow and Boulton, 2005). Both retinopathies show initially an increased FAF signal (Burke et al., 2014, Kellner et al., 2006, Kellner et al., 2008), referring to increased lipofuscin accumulation, and later bull’s eye-like lesion, when the RPE atrophy develops. However, in HCQ retinopathy the photoreceptor loss precedes the RPE atrophy (Rodriguez-Padilla et al., 2007, Chen et al., 2010, Marmor, 2012, Kellner et al., 2009), while in STGD1, the precise sequence of RPE/photoreceptor loss is less clear (Cideciyan et al., 2004, Glazer and Dryja, 2002, Burke et al., 2011, Gomes et al., 2009). All patients from our cohort had some degree of visible RPE involvement, with pigment mottling, flecks or BEM, indicating much earlier RPE damage than would be expected in HCQ retinopathy.

It has been proposed, that the ABCA4 gene could be involved in the development of HCQ-induced retinopathy (Shroyer et al., 2001). The incidence of toxic retinopathy in HCQ users is between 0.5–7.5% (Marmor et al., 2011, Melles and Marmor, 2014), and it is not fully understood why some users are predisposed to the toxicity. Shroyer et al found disease causing missense variants in the ABCA4 gene in two of eight patients thought to have HCQ maculopathy due to the history of HCQ use and classical appearance of HCQ maculopathy lacking in STGD1-associated dark choroid and lipofuscin flecks. These variants were not present in the control group, suggesting that carrying an ABCA4 mutation may increase the risk of HCQ retinopathy (Shroyer et al., 2001). In fact, one of the two patients was homozygous for missense mutation p.R2107H, but was thought to have HCQ maculopathy due to the classical appearance of this retinopathy. This mutation was also present in two of eight patients in our...
cohort with phenotypes resembling HCQ retinopathy. Moreover, these patients in our study (Paper 3) are of African descent and the p.R2107H variant was recently described as the most prevalent disease causing mutation in African-American patients with STGD1, exhibiting disease with milder phenotype and later-onset (Zernant et al., 2014a). Interestingly, a more recent study has found, on the contrary, that some ABCA4 missense variants may have a protective effect reducing the susceptibility to develop toxic retinopathy under chloroquine treatment (Grassmann et al., 2015).

6.3. Genotype-phenotype associations in STGD1

Genotype-phenotype associations are difficult to assess and detect in STGD1. First of all, there is remarkable allelic heterogeneity in STGD1 and secondly, harboring two different alleles in autosomal-recessive disorder makes it difficult to determine the combination effect, especially if the number of known ABCA4 disease-associated alleles is >1000. Therefore, large databases are needed with genotype and phenotype information, and possibly also some functional studies to detect the effects of individual alleles. However, we detected genotype-phenotype association in the optical gap phenotype. By genetic analysis of patients with the optical gap phenotype we confirmed that all were compound heterozygous for ABCA4 mutations. Interestingly, the p.G1961E variant was present in 10 of 11 unrelated cases (91%). The p.G1961E mutation is the most frequent disease associated ABCA4 allele seen in approximately 10% of STGD1 patients of European origin (Burke et al., 2012a). This fraction was almost the same in our cohort of 179 patients, including 157 unrelated individuals (42/157; 13.4%), but remarkably higher in patients with the optical gap phenotype (46.7% vs. 13.4%, \(p < 0.0001\)). It has to be noted, however, that while the optical gap phenotype is definitely associated with the p.G1961E variant, the reverse is not the case since a larger fraction (32 unrelated individuals) who harbored the p.G1961E allele did not present with the optical gap. Fourteen of these individuals were clinically characterized at the same age after onset as the optical gap group. Of the other disease-associated ABCA4 alleles compound heterozygous with p.G1961E, the p.L541P mutation, presenting alone or as a complex allele with the p.A1038V variant, was observed in seven cases (four unrelated) with the optical gap while only once in patients without the phenotype. However, due to a relatively small size of the optical gap cohort we cannot make an unequivocal conclusion about the association of this allele with the optical gap phenotype. With the exception of P13, the optical gap was not observed in the SD-OCT scans of any other non-p.G1961E patients (n = 131) whose age at time of examination, age of onset and estimated disease duration were not statistically different from those of the p.G1961E (n = 48) patients. Therefore the p.G1961E variant, maybe sometimes together with the p.L541P or p. (L541P; A1038V) allele, is associated with the optical gap phenotype. It is also interesting that p.L541P and p.(L541P; A1038V) alleles have been considered as severe alleles causing misfolding and reduction of ATPase activity of ABCA4 leading
to severe phenotypic expression (Zhang et al., 2015, Cideciyan et al., 2009), while in this case, the combination with p.G1961E allele, the phenotype in rather mild, indicating that the p.G1961E might have a “dominant” effect over the second mutation (Burke and Allikmets, 2013, Burke et al., 2014).

Genotype-phenotype association was not detected in the foveal sparing phenotype. However, the number of patients was very small. A study by Fujinami et al reported slightly higher frequency of p.R2030Q variant and lower incidence of p.G1961E ABCA4 variant in STGD1 patients with foveal sparing phenotype, however the association was not statistically significant (Fujinami et al., 2013d). None of our patients as well as patients in another study (van Huet et al., 2014) harbored the p.R2030Q variant. An etiological connection between foveal sparing and ABCA4 is further weakened by the incidence of foveal sparing phenotype in other genetically distinct retinal degenerative diseases such as PRPH2 pattern dystrophy and AMD (Boon et al., 2008, Schmitz-Valckenberg et al., 2009, Duncker et al., 2015). In addition, two patients in this cohort harbored the p.G1961E allele, which would explain the milder course of the disease, but it was somewhat surprising in the foveal sparing phenotype, as the allele is associated predominantly with the central macular disease with cone involvement (Cella et al., 2009). The same was demonstrated in Paper 2 that the optical gap phenotype with cone-predominant change is associated with p.G1961E allele. Furthermore, in another study with foveal sparing phenotype (van Huet et al., 2014), none of the patients harbored p.G1961E allele and in a cohort of 40 patients with preserved foveal FAF only one patient carried the p.G1961E mutation as opposed to higher p.G1961E allele frequency in non-foveal sparing patients (1.6% vs 6.1%) (Fujinami et al., 2013d). Therefore, in agreement with other studies there are probably other genetic or non-genetic factors contributing to foveal sparing phenomenon, which need to be further determined (Fujinami et al., 2013d, van Huet et al., 2014).
7. CONCLUSIONS

1. In addition to significant thinning of the photoreceptor-associated ellipsoid zone layer, there is a statistically significant thickening of the external limiting membrane in young STGD1 patients compared to the age-matched controls. The finding probably reflects a transient hypertrophy of retinal Müller cells in response to cellular stress at the photoreceptor level, and could clinically be an important early stage disease marker, holding a diagnostic potential in early diagnosis of the STGD1.

2. The optical gap phenotype in STGD1 can be structurally divided into 3 progressive developmental stages. Initially there is mild subfoveal disruption of the EZ followed by progressive expansion of the EZ loss resulting in optically empty space devoid of foveal photoreceptors. At the later stage of the disease, the optically empty space collapses followed by progressive neuroretinal and the RPE cell atrophy. In contrast to the common understanding, that the first cells being affected in STGD1 are the RPE cells, our study seems to support the finding of some other groups, that in the STGD1-associated optical gap phenotype, photoreceptor loss sequentially precedes the RPE degeneration, suggesting a different pathogenetic mechanism in this subgroup of patients.

   The visual acuity in these patients correlated well with the EZ integrity, therefore patients with Stage 1 optical gap had relatively spared central vision, compared with the patients having more severe ellipsoid zone loss in Stage 2 and Stage 3. All patients with the optical gap phenotype and available ffERG recordings had normal ffERG responses, indicating a localized disease process and better prognosis in terms of visual function.

   We detected that STGD1 could phenocopy HCQ toxic retinopathy. A variant of foveal sparing phenotype in STGD1 mimics an OCT sign associated with HCQ retinal toxicity, also called a “flying-saucer” sign. Furthermore, in addition to the similar SD-OCT phenotype presentation, some of the patients presented with classical HCQ retinopathy-like bull’s eye lesion on FAF and funduscopy lacking STGD1-characteristic flecks, therefore making phenotypic differentiation of these retinopathies difficult. Consequently, in more ambiguous cases ABCA4 screening should be considered to prevent possible misdiagnosis.

   The majority of patients with the variant of “foveal sparing” phenotype were asymptomatic with very good visual acuity due to the preserved foveal photoreceptors. All the patients, with available ERG recordings, had normal ffERG responses.

3. The optical gap phenotype in STGD1 is highly associated with p.G1961E mutation in ABCA4. The allele frequency of p.G1961E allele in patients with the optical gap phenotype was 46.7%, while in the entire STGD1 cohort of 179 patients (157 unrelated individuals) it was 13.4%, showing statistically a highly significant difference ($p < 0.0001$).
Stargardt disease exhibits remarkable phenotypic heterogeneity. Despite Mendelian inheritance, genotype-phenotype associations are difficult to detect due to the large number of disease causing mutations. However, modern retinal imaging methods enable clinicians and researchers to expand the knowledge of disease expression, and increase the possibility to detect the genotype-phenotype associations. Detailed phenotypic descriptions and dynamic assessment via multimodal imaging as well as detecting new genotype-phenotype associations potentially improve the planning of pharmacological, gene- and stem cell-based treatment studies of STGD1.
8. REFERENCES


60


Ma, W., Zhao, L. & Wong, W. T. 2012. Microglia in the Outer Retina and Their Relevance to Pathogenesis of Age-Related Macular Degeneration, Springer US.


9. SUMMARY IN ESTONIAN

Autosoom-retsessiivne Stargardti tõbi: fenotüübiline heterogeensus ja genotüübi-fenotüübi seosed

Stargardti tõbi (STGD1) on kõige sagedasem pärlik kollatähtü düstroofia, mille esinemissageduseks hinnatakse olevat 1:8000–1:10 000 (Michaelides et al., 2003). Haigus on põhjustatud ABCA4 geeni defektist, mille tulemusena häirub fotoretseptorites paikneva ning visuaaltsüklis olulise ABCA4 transporteri töö (Allikmets et al., 1997b, Molday and Zhang, 2010). Haiguse tulemusena koguneb võrkkestas pigmentepiteeli (RPE) rakkudes toksiline ühend (lipofustsiin), mis viib RPE rakkude ja fotoretseptorite kaole. Samas on siiani diskussiooniks, kas primaaresselt hävivad RPE rakud, viies sekundaarselt fotoretseptorite kaole, või toimub fotoretseptorites juba varem destruktiivseid kahjustusi (Cideciyan et al., 2004, Sparrow and Boulton, 2005, Duncker et al., 2014, Gomes et al., 2009).

Arvestades, et STGD1 on autosoom-retsessiivse pärlikkusega haigus ning kirjeldatud on enam kui 1000 haigust ja seosega 1:40 000–1:10 000 (Burke and Tsang, 2011). Fenotüübiliselt on STGD1 haigeid jaotatud vastavalt võrkkestast haareltusele nelja staadiumisse, kus esimene staadium väljendub isoleeritud kollatähtühina haigusena ja neljas staadium laiaulatusliku korioretinaalse atroofiana (Fishman, 1976). Elektrofüsioloogiliselt on samuti kirjeldatud erinevaid STGD1 fenotüüpe (Lois et al., 2001). Esineb haigeid, kellel on normaalne kepikeste ja kolvikeste massvastus, kuid ka neid, kellel kolvikeste või nii kolvikeste kui ka kepikeste funktsioon on oluliselt langenud (Lois et al., 2001). Haigus on enamasti varajase algusega ning sümpтомid tekivad tavaliselt teisel eludekaalil, kuid esineb ka hilis- algusega STGD1, kus haiguse sümpтомid avalduvad tunduvalt hiljem (Westeneng-van Haaften et al., 2012).

Võrkkesta muutuste detailedseks hindamiseks on kasutusel mitmeid võrkkestatuvimiseseid, millest olulisemad on optiline koherentne tomograafia (SD-OCT) ja silmapõhja autofluorestsents- uuring (FAF). Esimene võimaldab visualiseerida erinevaid võrkkestast kahte, kuvades in vivo histoloogilise pildi, ning teine, autofluorestsents kuvamisprotsess, võimaldab hinnata lipofustsiini distributiooni ja RPE rakkude terviklikku (Boon et al., 2008). Klassikaliselet on varajasteks STGD1 iseloomulikeks kliiniliseks leidudeks tähnilised kollakad ladestused ja kollatähtühina atroofia, mis võrkkast kuvamisprotsessel väljenduvad lipofustsiini kogunemisest tekkeva autofluorestsents-signaali intensiivistumisenega ja kollatähtühina piirkonna välisreeta atroofiana (Michaelides et al., 2003, Cideciyan et al., 2004, Huang et al., 2014). Samas võimaldavat detailedse kuvamisprotsedura laiendada STGD1 fenotüübilist spektri veelgi. Nüüdseks on STGD1 puhul kirjeldatud nii „foveal säilitavat“ (ingl.k foveal sparing) fenotüüpi kui ka fovea tühimikku (ingl.k optical gap; foveal cavititation) (Fujinami et al., 2013d, van Huet et al., 2014, Leng et al., 2012). Kumbki fenotüüp ei ole spetsiifiline STGD1, vaid on kirjeldatud mitmete erinevate võrkkaste düstroofiate korral.
(Greenberg et al., 2014, Park et al., 2010, Sergouniotis et al., 2012). Foveat säilitava fenotüübi korral püsib võrkkesta terava nägemise punkt (fovea) suhteliselt kaua muutumatuna, vaatamata külallalt väljendunud leiule mujal võrkkestas, mistõttu säilib nägemisteravus suhteliselt kaua (van Huet et al., 2014). Fovea tühimik on aga SD-OCT-l ilmestuv fenotüüp, kus fovea fotoretseptorite kaost tekkib strukturne tühimik fovea piirkonna võrkkestas väliskihti (Leng et al., 2012).

Genotüübi-fenotüübi seoseid on STGD1 puhul keeruline leida ja analüüsida, kuna esineb väga suur alaeline heterogeensus ning sama alaeline kombinatsiooniga patsientide esineb harva. Lisaks võib fenotüüp olla külalt erinev ka sama alaeline kombinatsiooniga patsientidel, viidates haigust modifitseerivatele geenidele või keskkonna faktoritele (Lois et al., 1999, Michaelides et al., 2007). Varasemad uuringud on viidanud, et fenotüübi raskuse määramisele peaks olla enamasti sama alleelse kombinatsiooniga patsientidel, vaikaks võib ehitada, et fovea fotoretseptorite kaost esineb strukturne tühimik fovea piirkonna võrkkestas väliskihti (van Huet et al., 2014). Fovea tühimik on aga SD-OCT-l ilmestuv fenotüüp, kus fovea fotoretseptorite kaost tekkib strukturne tühimik fovea piirkonna võrkkestas väliskihti (Leng et al., 2012).

Genotüübi-fenotüübi seoseid on STGD1 puhul keeruline leida ja analüüsida, kuna esineb väga suur alaeline heterogeensus ning sama alaeline kombinatsiooniga patsiente esineb harva. Lisaks võib fenotüüp olla külalt erinev ka sama alaeline kombinatsiooniga patsientidel, viidates haigust modifitseerivatele geenidele või keskkonna faktoritele (Lois et al., 1999, Michaelides et al., 2007). Varasemad uuringud on viidanud, et fenotüübi raskuse määramisele peaks olla enamasti sama alleelse kombinatsiooniga patsientidel, vaikaks võib ehitada, et fovea fotoretseptorite kaost esineb strukturne tühimik fovea piirkonna võrkkestas väliskihti (van Huet et al., 2014). Fovea tühimik on aga SD-OCT-l ilmestuv fenotüüp, kus fovea fotoretseptorite kaost tekkib strukturne tühimik fovea piirkonna võrkkestas väliskihti (Leng et al., 2012).


Uurimistöö eesmärgid
- Analüüsida varaseid võrkkesta struktuurimuutuseid noortel STGD1 haigetel.
- Leida, kirjeldada ja analüüsida optisilisel koherentsel tomograafial ilmestuvaid STGD1 fenotüüpe ja hinnata nende fenotüüpidega kaasnevat võrkkestast funktsiooni.
- Leida ja kirjeldada võimalikke Stargardti tõvega esinevaid genotüübi-fenotüübi seoseid.

Patsiendiid ja meetodid
Uurimustöös kasutati Columbia Ülikooli silmakliiniku pärilike võrkkestas ehk reetina düstroofiate andmebaasi, mis sisaldab endast ka geneetiliselt kinnitatud STGD1 haiget. Andmebaasis oli kahe esimese uuringu teostamise ajaks 179 STGD1 haiget, kellele olid teostatud nii SD-OCT kui ka FAF uuringud. Kuna andmebaas on ajas piidevalt täiendatud, siis kolmanda uuringu teostamise ajaks oli vastavate võrkkestas kuvamisuuringutega STGD1 haigete arv 200.

Võrkkestas struktuuri analüüsiseks kasutasime silmapõhja fotosid, SD-OCT ja FAF kuvamisuuringuid. Funktsiooni hindamiseks kasutasime nägemis-
teravuse määrust, multifokaalset ja täisvälja elektroretinograafiat (ERG). Geenianalüüs oli esimesesse uuringusse kaasatud patientidel teostatud ABCA4 geenikiibiga või järgmise põlvkonna ja Sangeri sekveneerimisega. Teise ja kolmandasse uuringusse kaasatud patientidel oli geenianalüüs teostatud vaid järgmise põlvkonna ja Sangeri sekveneerimisega.

Kuna esimeses uuringus soovisime hinnata varased võrkkestu struktuurimuutuseid ning STGD1 puhused sümptomid kujunevad välja tavaliselt 20ndateks eluaastateks, siis kaasasime uuringusse kõik STGD1 haiged, kelle võrkkesta struktuurianalüüsis vajalikud kuvamisuuringud olid teostatud enne 20. eluaastat (keskmne haiguskestvus oli 3,2 a). Kokku leidsime 179st haigest 26 vastava kriteeriumile vastavat STGD1 juhtu (keskmne vanus 12,9 a; vahe 5–19 a). Haigetel mõõdeti ja analüüsiti SD-OCT piltidel võrkkesta ellipsoidtsooni (iseloomustab fotoretseptorite terrviklikkust) ja välise piirimembrani paksust ja reflektiivsust kasutades Heidelberg Explorer tarkvara ja ImageJ programmi. Tulemusi võrreldi 30 kontrolluuritava (keskmne vanus 12,5 a; vahe 4–20 a) võrkkesta vastavate parametretega.

Teises uuringus uurisime fovea tühimikuga STGD1 haigete fenotüübi dünaamilist kujunemist ning mutatsioonide profiili (ehk geenikiib-fenotüübi seost). Vaadates läbi 179 STGD1 haige SD-OCT ülesvõtted, leidsime 15 haiget, kellel esines kirjeldatud fenotüüp.

Kolmandas uuringus kirjeldasime ja analüüsime SD-OCT ülemist fovea tühimiku jaotamist 3 arenguvaadiatorisse. Algfaasis esineb kõrgaks fovea aluse ellipsoidtsooni granulaarsus, mis progresseerudes viib sellega fotoretseptorite tasandil erinevatele stressile. Välise piirimembrani paksunemine võib olla STGD1 varajaseks fenotüübiga. Analüüsime ja kirjeldasime STHGD1 haigete kuvamisuuringute, funktsiooni ja ABCA4 geeniuuringute tulemusi.

**Peamised tulemused ja järeldused**

1) Lisaks klassikalisele seisukohale, kus STGD1 haigetel tekib võrkkesta väliskihtide atroofia, näitasime, et noortel STGD1 haigetel esineb lisaks võrkkesta fotoretseptorite iseloomustava kiihi (ellipsoidtsooni) õhenemisele võrkkesta välise piirimembrani statistiliselt oluline paksunemine võrreldes kontrollgrupiga. Leid võib viidata võrkkesta Mülli rakkude mõõduvate hypertroofialiste vastusega fotoretseptorite tasandil esinevate stressile. Välise piirimembrani paksemine võib olla STGD1 varajaseks fenotüübiga. Analüüsime, et klassikaline arusaam STGD1 patogeneesist, kui tüüpline STGD1 iseloomulik fenotüüp ei pruugi olla veel välja kujunenud.

2) Võrkkesta kuvamisuuringute analüüs saab STGD1 esinevat fovea tühimiku jaotada 3 arenguvaadiatorisse. Algfaasis esineb kerge fovea aluse ellipsoidtsooni granulaarsus, mis progresseerudes viib sellega fenotüübi moodustumiseni. Lõppfaasis tühimik kaob, millele järgneb neuroreeta ja RPE atroofia. Sarnaselt mitmetele teistele uuringutele näitasime ka meie, et klassikaline arusaam STGD1 patogeneesist, kus primargalt esineb lipofoot-
siinist põhjustatud RPE atroofia, millele järgneb sekundaarne fotoretseptorite kadu, ei kehti kõikidele STGD1 haigetele. Kirjeldatud fenotüübiga haigetel esineb primaarselt just fotoretseptorite kadu, viidates võimalikule alternatiivsele patogeneesimehanismile.

Kirjeldatud struktuuimuutusega patsientidel korelleerub nägemisteravus ellipsoidsooni terviklikkusega, seetõttu on 1. staadiumi fovea tühimikuga patsientidel nägemisteravus suhteliselt vähe langenud erinevalt 2. ja 3. staadiast, kus ellipsoidsoon on rohkem haaratatud. Köigil fovea tühimikuga STGD1 haigetel, kellel oli ERG tehtud, olid täisvälja ERG vastused normis, viidates lokaalsele haigusprotsessile ning paremale haiguse prognoosile.


3) Fovea tühimik on STGD1 korral tugevalt seotud p.G1961E mutatsiooniga ABCA4 genees. Fovea tühimikuga haigete hulgad p.G1961E alleeli sagedus 46,7%, samas kui kogu STGD1 hulgast oli alleeli sagedus 13,4% ($p < 0.0001$).

Stargardti tõve iseloomustab märkimisväärne fenotüübulline heterogeensus. Kasutades kaasaegseid võrkkesta kuvamisuuringuid, analüüsime võrkkesta väliskihtide varajasi struktuurimuutuseid, SD-OCT-i ilmestuvaid fenotüüpe ja kirjeldamise genotüübi-fenotüübi seost STGD1 haigetel. Fenotüüpide detailne iseloomustamine, dünaamika hindamine ja genotüübi-fenotüübi seoste kirjeldamine võiks potentsiaalisest paremini aidata planeerida ja analüüsida ravimi, geeniteraapia ja tüvirakuteraapia uuringuid ning nende tulemusi STGD1 kontekstis.
10. ACKNOWLEDGEMENTS

The current studies were carried out at the Department of Ophthalmology, Columbia University, during my stay there as a research fellow. Working and studying in such a motivated, inspiring and supporting environment has been truly a lifetime experience.

This study was supported by grants from the National Eye Institute/National Institutes of Health (Bethesda, MD, USA) EY021163, EY019861, and EY019007 (Core Support for Vision Research), Foundation Fighting Blindness (Owings Mills, MD, USA), and an unrestricted funds from Research to Prevent Blindness (New York, NY, USA) to the Department of Ophthalmology, Columbia University.

I wish to thank Tartu University Hospital for supporting my PhD studies by nominating me for Tartu University Hospital PhD project scholarship.

I wish to express my sincere gratitude to all the people who have helped me in the present work, special thanks to:

− My supervisor Professor Rando Allikmets, who brought me to Stargardt disease enabling me to work with his team at the Columbia University. His mentorship has been vital for the present work and I wholeheartedly thank him for the opportunities he has given me.

− My supervisor Doctor Kuldar Kaljurand for the support and advice during my studies in the PhD program as well as in ophthalmology training in general. I would not have accomplished many things in my career without his support.

− My colleague and a good friend Winston Lee, without his help, support and motivation this work would not have been accomplished.

− Associate Professor Stephen H Tsang and Professor Stanley Chang from Columbia University Medical Center for enabling me to work with them. I learned a lot from them, their attitude towards research in general has been an important motivator.

− My colleagues in the Eye Clinic of Tartu University Hospital for their support and encouragement.

− Medical and research stuff at Columbia University, Department of Ophthalmology, for their kindest help and support.

− Professor Marina Aunapuu and Professor Andres Arend for introducing me the scientific work during my undergraduate studies by making it a very pleasant experience.

− Professor Pille Taba and Professor Katrin Õunap for reading and commenting on the thesis.

− My beloved Paula, my parents and sister for their support, patience and understanding during my PhD studies in Estonia and abroad.

− My lovely Emma, who has turned a new page in my life.
11. PUBLICATIONS
CURRICULUM VITAE

Name: Kalev Nõupuu
Date of birth: 09.06.1985, Tallinn, Estonia
Citizenship: Estonian
Address: 8 L. Puusepa Street, 51014, Tartu, Estonia
Phone: 7319 762
E-mail: kalev.noupuu@kliinikum.ee

Education and employment:
1993–2004  Tallinna Üldgümnaasium (Gold medal)
2004–2010  University of Tartu, Faculty of Medicine, Degree in Medicine
2010–2013  University of Tartu, Faculty of Medicine, Residency training in ophthalmology
2013  European Board of Ophthalmology (EBO) exam passed, Paris, France
2013–  University of Tartu, Faculty of Medicine, PhD studies in ophthalmology
2013–2014 Columbia University, Edward S. Harkness Eye Institute, Postdoctoral Research Fellow, New York, the United States
2015–  University of Tartu, Faculty of Medicine, Residency training in ophthalmic surgery subspecialty

Scientific work and professional organizations
Research fields: Retinal imaging, retinal dystrophies, Stargardt disease
Publications: 5 international
Membership: Estonian Ophthalmology Society, Fellow of European Board of Ophthalmology (FEBO)

List of publications
*Equivalent authors
ELULOOKIRJELDUS

Nimi: Kalev Nõupuu
Sünniaeg: 09.06.1985, Tallinn, Eesti
Kodakondsus: Eesti
Aadress: L. Puusepa 8, Tartu 51014, Eesti
Telefon: 7319 762
E-post: kalev.noupuu@kliinikum.ee

Haridus- ja ametikäik:
1993–2004 Tallinna Üldgümnaasium (kuldmadal)
2004–2010 Tartu Ülikool, arstiteaduskond, arstiööpe
2010–2013 Tartu Ülikool, arstiteaduskond, silmahaiguste residentuur
2013 Euroopa Oftalmoloogia Erialaseltsi eksami sooritus, Pariis, Prantsusmaa
2013– Tartu Ülikool, arstiteaduskond, doktoriööpe silmahaiguste erialal
2013–2014 Columbia Ülikool, Edward S. Harkness Eye Institute, õppe- ja teadustöö, New York, USA
2015– Tartu Ülikool, arstiteaduskond, silmakirurgia kõrvaleralada residentuur

Teadus- ja erialane tegevus
Valdkonnad: Reetina kuvamisuuringud, reetina düstroofiad, Stargardti tõbi
Publikatsioonid: 5 rahvusvahelist eriala publikatsiooni
Liikmelisus: Eesti Oftalmoloogide Selts
Euroopa Oftalmoloogia Erialaseltsi liige

Publikatsioonide nimekiri:
*N=Equivalent authors


18. **Aavo Lang.** The role of dopamine, 5-hydroxytryptamine, sigma and NMDA receptors in the action of antipsychotic drugs. Tartu, 1995.

24. **Paavo Pokk.** Stress due to sleep deprivation: focus on GABA<sub>A</sub> receptor-chloride ionophore complex. Tartu, 1996.
32. **Joel Starkopf.** Oxidative stress and ischaemia-reperfusion of the heart. Tartu, 1997.
34. **Ülla Linnamägi.** Changes in local cerebral blood flow and lipid peroxidation following lead exposure in experiment. Tartu, 1998.
38. **Allen Kaasik.** Thyroid hormone control over β-adrenergic signalling system in rat atria. Tartu, 1998.


72. **Ade Kallas.** Characterization of antibodies to coagulation factor VIII. Tartu, 2002.

73. **Heidi Annuk.** Selection of medicinal plants and intestinal lactobacilli as antimicrobial components for functional foods. Tartu, 2002.


100. **Aune Rehema.** Assessment of nonhaem ferrous iron and glutathione redox ratio as markers of pathogeneticity of oxidative stress in different clinical groups. Tartu, 2004.


104. **Kersti Kokk.** Regulation of active and passive molecular transport in the testis. Tartu, 2005.


112. **Andres Sell.** Determining the minimum local anaesthetic requirements for hip replacement surgery under spinal anaesthesia – a study employing a spinal catheter. Tartu, 2005.


181. Delia Lepik. Comparison of gunshot injuries caused from Tokarev, Makarov and Glock 19 pistols at different firing distances. Tartu, 2011.


211. **Merit Lamp.** Genetic susceptibility factors in endometriosis. Tartu, 2013, 125 p.


221. **Irina Kerna.** The contribution of *ADAM12* and *CILP* genes to the development of knee osteoarthritis. Tartu, 2014, 152 p.


236. **Anna Klugman.** Functionality related characterization of pretreated wood lignin, cellulose and polyvinylpyrrolidone for pharmaceutical applications. Tartu, 2015, 156 p.


